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In 2008, cancer killed almost eight million people and that 
number is predicted to increase. A large proportion of human 
cancers are preventable; many cancers have environmental risk 
factors, such as tobacco smoking and work-related exposures. 
Carcinogenesis is driven by alterations in the sequence and func-
tion of genes involved in many crucial cellular processes. Under-
standing these molecular mechanisms will clarify the role and 
biological effects of these risk factors. 
 
In this work, mutations in the tumour suppressor gene, TP53, and 
their associations with exposure were studied in sinonasal can-
cer and lung cancer. Another important mechanism in cancer is 
inflammation and its contribution was explored by analyzing the 
expression of COX-2 in sinonasal cancer.
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Syöpä on yksi yleisimmistä kuolinsyistä maailmanlaajuisesti ja sairas-
tuneiden määrä on kasvussa. Monet näistä syövistä, esimerkiksi nenän 
alueen syöpä ja keuhkosyöpä, liittyvät erilaisiin ympäristötekijöihin, 
joten ne ovat mahdollisesti ehkäistävissä. Nenän alueen syöpä liittyy 
vahvasti työperäiseen puupölyaltistumiseen, kun taas keuhkosyövän 
tärkein riskitekijä on tupakointi. Keuhkosyövän kehittymiseen johta-
via molekyylitason mekanismeja on tutkittu laajasti, mutta sen sijaan 
nenän alueen syöpään liittyvistä molekyylitason muutoksista on tähän 
mennessä tiedetty hyvin vähän. Tässä väitöskirjatyössä on tutkittu TP53-
kasvurajoitegeenin mutaatioita nenän alueen syövässä ja keuhkosyövässä 
sekä tulehduksiin liittyvän proteiinin COX-2 ilmenemistä nenän alueen 
syövässä sekä näiden tekijöiden liittymistä altistumiseen riskitekijöille. 
Tulokset osoittavat, että TP53-geenin mutaatiot ovat yleisiä sekä nenän 
alueen syövässä että keuhkosyövässä ja näissä molemmissa muutokset liit-
tyvät altistumiseen. Nenän alueen syövissä mutaatioita esiintyi enemmän 
tapauksilla, jotka olivat työssä altistuneet pitkään ja suhteellisen suurille 
pitoisuuksille puupölyä. Tupakointi ei vaikuttanut nenän alueen syövissä 
suorasti mutaatioiden esiintymiseen, vaan se liittyi useamman kuin yhden 
mutaation esiintymiseen samaan aikaan yksittäisessä syövässä. Lisäksi 
vaikuttaa siltä, että tulehdusvaikutukset ovat yksi puupölyaltistumiseen 
liittyvän nenän alueen syövän kehittymisen mekanismeista, sillä COX-
2-proteiinin ilmeneminen liittyi erityisesti adenokarsinomasolutyyppiin, 
puupölyaltistumiseen ja tupakoimattomuuteen. Keuhkosyövässä TP53-
mutaatioiden esiintyminen liittyi pitkään tupakointiaikaan, kasvaimen 
solutyyppiin ja sukupuoleen. Lisäksi osoitimme, että tupakoijille tyypil-
lisen mutaatiotyypin (G>T) kantajilla oli normaalissa keuhkokudoksessa 
suuri määrä tupakointiin liittyviä DNA-vaurioita. Tämänkaltainen 
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tieto molekyylitason muutoksista ympäristöperäisissä syövissä täydentää 
epidemiologisista tutkimuksista saatua tietoa ja auttaa selventämään 
eri syytekijöiden osuutta ja niiden vaikutustapoja. Tämä puolestaan on 
tärkeää terveysriskien arvioimisessa ja ehkäisyssä.
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Cancer is a leading cause of death worldwide and the total number of 
cancer cases continues to increase. Many cancers, for example sinonasal 
cancer and lung cancer, have clear external risk factors and so are poten-
tially preventable. # e occurrence of sinonasal cancer is strongly associ-
ated with wood dust exposure and the main risk factor for lung cancer is 
tobacco smoking. Although the molecular mechanisms involved in lung 
carcinogenesis have been widely studied, very little is known about the 
molecular changes leading to sinonasal cancer. In this work, mutations 
in the tumour suppressor TP53 gene in cases of sinonasal cancer and 
lung cancer and the associations of these mutations with exposure fac-
tors were studied. In addition, another important mechanism in many 
cancers, infl ammation, was explored by analyzing the expression of the 
infl ammation related enzyme, COX-2, in sinonasal cancer. # e results 
demonstrate that TP53 mutations are frequent in sinonasal cancer and 
lung cancer and in both cancers they are associated with exposure. In 
sinonasal cancer, the occurrence of TP53 mutation signifi cantly increased 
in relation to long duration and high level of exposure to wood dust. 
Smoking was not associated with the overall occurrence of the TP53 
mutation in sinonasal cancer, but was associated with multiple TP53 
mutations. Furthermore, infl ammation appears to play a part in sinonasal 
carcinogenesis as indicated by our results showing that the expression 
of COX-2 was associated with adenocarcinoma type of tumours, wood 
dust exposure and non-smoking. In lung cancer, we detected statisti-
cally signifi cant associations between TP53 mutations and duration 
of smoking, gender and histology. We also found that patients with a 
tumour carrying a G to T transversion, a mutation commonly found in 
association with tobacco smoking, had a high level of smoking-related 
6+,$!-+.!
bulky DNA adducts in their non-tumorous lung tissue. Altogether, the 
information on molecular changes in exposure induced cancers adds to 
the observations from epidemiological studies and helps to understand 
the role and impact of diff erent etiological factors, which in turn can be 
benefi cial for risk assessment and prevention.
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# is thesis is based on the following original publications, which are 
referred to in the text by their Roman numerals (I–V):
I.  Holmila R and Husgafvel-Pursiainen K. (2006). Analysis of 
TP53 gene mutations in human lung cancer: Comparison of 
capillary electrophoresis single strand conformation polymor-
phism assay with denaturing gradient gel electrophoresis and 
direct sequencing. Cancer Detect Prev, 30(1) 1–6.
II.  Holmila R, Cyr D, Luce D, Heikkilä P, Dictor M, Steiniche T, 
Stjernvall T, Bornholdt J, Wallin H, Wolff  H, Husgafvel-Pur-
siainen K. (2008) COX-2 and p53 in human sinonasal cancer: 
COX-2 expression is associated with adenocarcinoma histology 
and wood-dust exposure. Int J Cancer, 122(9) 2154–2159.
III.  Anna L*, Holmila R*, Kovács K, Gyorff y E, Gyori Z, Segesdi 
J, Minárovits J, Soltész I, Kostic S, Csekeo A, Husgafvel-
Pursiainen K, Schoket B. (2009) Relationship between TP53 
tumour suppressor gene mutations and smoking-related bulky 
DNA adducts in a lung cancer study population from Hungary. 
Mutagenesis 24(6) 475–480, *Equal contribution. 
IV.  Holmila R, Bornholdt J, Heikkilä P, Suitiala T, Fevotte J, Cyr 
D, Hansen J, Snellman S-M, Dictor M, Steiniche T, Sclüns-
sen V, Schneider T, Pukkala E, Savolainen K, Wolff  H, Wallin 
H, Luce D, Husgafvel-Pursiainen. (2009) Mutations in TP53 
tumor suppressor gene in wood dust related sinonasal cancer. 
Int J Cancer, Nov 30. DOI:10.1002/ijc.25064
V.  Holmila R, Bornholdt J, Suitiala T, Cyr D, Dictor M, Steiniche 
T, Wolff  H, Wallin H, Luce D, Husgafvel-Pursiainen K. (2009) 
Profi le of TP53 gene mutations in sinonasal cancer. Mutat Res 
– Fundam Molec Mech Mutagenesis, 686(1–2) 9–14.
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A  Adenine
APC  Adenomatous polyposis coli 
ATM  Ataxia telangiectasia mutated
Bcl-2  B-cell CLL/lymphoma 2
BPDE  Benzo[a]pyrene diolepoxide
BRCA1  Breast cancer 1, early onset
BRAF1  Murine sarcoma viral (v-raf ) oncogene homolog B1
CBP  CREB binding protein
C  Cytidine
CE  Capillary electrophoresis
CI  Confi dence interval
COX-1  Cyclooxygenase-1
COX-2  Cyclooxygenase-2
DGGE  Denaturing gradient gel electrophoresis
EGFR  Epidermal growth factor receptor
G  Guanine
HRAS  v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
Hupki  Human p53 Knock-in
IARC   International Agency for Research on Cancer
ICD  International Statistical Classifi cation of Diseases and 
Related Health Problems
IL-1?  Interleukin-1?
KRAS  v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
M  Mutant
MDM2  Murine double minute 2
MYC  v-myc myelocytomatosis viral oncogene homolog 
NF1  Neurofi bromin 1
NF-?B  Nuclear factor-?B
NKK  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
NNN  N'-nitrosonornicotine
NSCLC  Non small cell lung cancer
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p16/INK4a  CDKN2A, cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4)
11
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p21/WAF1/ Cip1 CDKN1A, cyclin-dependent kinase inhibitor 1A
p300 E1A binding protein p300
p53 Tumour protein p53 
p63 Tumour protein p63
p73 Tumour protein p73
PAH Polycyclic aromatic hydrocarbon
PCR Polymerase chain reaction
PET Paraffi  n embedded tissue
PTEN Phosphatase and tensin homolog
RAS Ras (rat sarcoma viral oncogene homolog) oncogene 
 family
RB Retinoblastoma
RET Ret proto-oncogene
ROS Reactive oxygen species
RNS Reactive nitrogen species
SH3 Src homology 3 domain (proline rich binding)
SCLC Small cell lung cancer
SNP Single-nucleotide polymorphism
SSCP Single strand conformation polymorphism
STAT3 Signal transducer and activator of transcription 3 
(acute-phase response factor)
SV40 Simian virus 40
T # ymine
TNF-? Tumour necrosis factor-?
TP53 TP53 tumour suppressor gene
UV Ultraviolet
WHO World Health Organization
WT Wild type
WT1 Wilms tumour 1
XPA Xeroderma pigmentosum, complementation group A
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Cancer is the leading cause of death worldwide and the total number of 
cancer continues to climb. # is trend will most likely continue globally 
with the growth and ageing of the world’s population 1. Importantly, 
evidence from epidemiological studies suggests that a large proportion of 
human cancer can be attributed to environmental factors, if one defi nes 
the “environment” to include a wide range of exposures and lifestyle 
factors such as occupational exposure and dietary, social and cultural 
habits 2. # ese potentially preventable cancers include a wide variety of 
human cancers, especially those associated with tobacco smoking and 
work-related exposures, exemplifi ed by lung cancer and sinonasal cancer. 
Tobacco smoking and asbestos exposure are two of the most important 
causative factors of lung cancer 3–5, the most deadly of all human cancers 
with 1,3 million deaths per year globally 6, whereas sinonasal cancers 
represent a very rare form of cancer with a strong association to wood 
dust exposure at work 7–10. 
Carcinogenesis is driven by changes in sequence and function of the 
genes that control cell proliferation, survival and other physiological proc-
esses know to be altered in malignant cell types 11–15. Knowledge of these 
molecular mechanisms is important for the evaluation and prevention of 
health risks. Mechanistic information on cellular processes and changes 
in carcinogenesis complements the observations from epidemiological 
studies and helps to understand the role and eff ect of diff erent etiological 
factors. # is kind of data may also eventually open prospects for treat-
ment. At present, molecular mechanisms in some cancers, such as lung 
cancer, have been widely studied, whereas for some others, for example 
sinonasal cancer, very little is known about the molecular changes in-
volved in cancer development.
13
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Mutations of the tumour suppressor TP53 gene are an important 
feature in many human cancers, as the elimination of TP53 pathway 
appears to be requisite at some point of carcinogenesis in most, if not 
all, human cancers 16. Certain carcinogenic exposures have been shown 
to induce a typical and recognizable TP53 mutation spectrum, which 
makes it a highly interesting gene in the search for molecular mechanisms 
of cancer in association to external exposures. 
# e studies in this PhD-thesis investigated molecular changes, with 
the emphasis on TP53 mutations, in sinonasal cancer and in lung cancer 
and searched for their associations with exposure. Infl ammation, which 
is another important mechanism involved in carcinogenesis in many 
types of human cancer, was investigated by analyzing the expression of 
the infl ammation related enzyme, COX-2, in sinonasal cancer.
14
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Cancer is a group of diseases characterized by aberrant cellular growth. 
It aff ects many diff erent tissues and types of cell, and is often defi ned by 
the tissue of origin. Cancer aff ects more people in our time than it did 
in the past due to the increase and aging of world population 2, 17. # e 
International Agency for Research on Cancer (IARC) has estimated that 
globally in the year 2008 12.4 million cases of cancer were diagnosed, 
7.6 million patients died from cancer and 28 million persons were alive 
with cancer within fi ve years from the initial diagnosis 2. 
# e most commonly diagnosed cancers (excluding all types of skin 
cancer) are those of the lung, colon and rectum and breast 17. In men, 
lung cancer is the most common cause of death related to cancer, whereas 
in women breast cancer is the principal killer 2. Nevertheless, the patterns 
of cancer trends, incidence, and projections vary greatly in the diff erent 
parts of the world 17. Many of the cancers could potentially be prevented 
as several risk factors are already known. In most cancers, environmental 
factors seem to play greater part in the acquisition of cancer than in-
herited susceptibility 1, 18, 19. # e known risk factors for cancer include 
certain lifestyle factors (tobacco and alcohol use, diet, obesity, physical 
inactivity), exposure to occupational or environmental carcinogens (for 
example, asbestos and wood dust), radiation (for example, ultraviolet 
and ionizing radiation) and some viral infections (for example, hepa-
titis B or human papilloma virus infection) 1. # ese factors can aff ect 
carcinogenesis at diff erent stages through both genetic and epigenetic 
mechanisms 6, 18. 
15
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Most, if not all, cancers start with alterations in one or a small 
number of cells 12, 20. # ere is increasing evidence that these cells are 
likely to be cancer stem cells, i.e. cells that have the ability to prolifer-
ate and generate the vast array of diff erent cells found in a tumour 11, 21, 
22. # e development of cancer is a multistep process driven by genetic 
and epigenetic changes where cells undergo metabolic and behavioral 
changes, leading them to lose control of normal replication and growth 
12, 17, 20. As proposed by Hanahan and Weinberg 14, six essential cellular 
characteristics are shared by most, possibly all, types of human tumours : 
self-suffi  ciency in growth signals, insensitivity to growth-inhibitory sig-
nals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis 14. 
Infl ammation might well be an equally important feature 23. 
If a cell with alterations in critical cell functions is tolerated by the 
organism, it may accumulate even more modifi cations when proliferating 
and eventually become highly malignant 12, 20. Somatic mutations that 
contribute to the acquisition of the essential tumour properties drive the 
transformation of normal human cells into malignant tumour cells while 
making this process irreversible 14, 15. # e order and way of acquiring 
the diff erent malignant capacities varies widely, even among tumours of 
the same type and certainly between tumours of diff erent types. Also, in 
certain tumours a specifi c genetic event may contribute only partially to 
the acquisition of a single capability, while in others the same event may 
result in simultaneous acquisition of several distinct capabilities 14. 
Furthermore, tumours are complex tissues that depend on interac-
tion between various cells found in the tumour stroma 24. # e stroma 
consists of non-malignant cells of a tumour, the vasculature and its cells, 
the activated fi broblasts, macrophages and other immune cells 24–26 and 
the cancer cells can alter the stroma to form a permissive and supportive 
environment for tumour progression 26. # e interactive signaling between 
stromal and tumour cells contributes to the formation of a multicellular 
tumour 26. 
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Approximately 23 000 genes are present in the human genome and several 
thousand (3000–5000) encode proteins involved in cellular processes 
16
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deregulated in cancer. Of these, about 300 diff erent genes are mutated 
at some frequency in human cancers, however, large-scale re-sequencing 
studies on cancer genomes have detected only a relatively small number 
of genes as being commonly mutated in human cancers, whereas most 
of the mutations found in tumours are infrequent in general 12, 22, 27, 28. 
Also, the genes mutated in cancer appear to be a part of a small number 
of pathways, like the 12 core pathways identifi ed in pancreatic cancer 
11, 29. 
# e genes involved in tumorigenesis include oncogenes like the RAS 
family genes, -Catenin, BRAF1, tumour suppressor genes like TP53, 
APC, p16/INK4a, PTEN, and genomic stability genes like BRCA1, ATM, 
XPA 11, 15. Proteins coded by oncogenes promote cell proliferation 30 and 
are activated by genetic alterations in cancer whereas tumour suppressor 
genes become deactivated. Under normal conditions, tumour suppressor 
genes function against clonal expansion and genomic mutability and are 
therefore able to inhibit uncontrolled growth and metastasis 31. Stability 
genes, or caretaker genes, include the genes responsible for DNA repair 
and the control of mitotic recombination and chromosomal segregation. 
# eir function is to keep genetic alterations to a minimum and if those 
genes become inactivated, the mutations will become more frequent 11. 
Germline mutations in the genes involved in tumorigenesis lead to a 
predisposition to cancer, but other alterations in the cell’s genome are still 
needed before the transformation of the cell into a cancer cell. Carriers 
of a germline mutation in a tumour predisposing gene often develop 
multiple cancers that occur at an earlier age as compared to individuals 
who acquire such mutations somatically 11, 13.
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Genetic alterations occur regularly in the DNA of all organisms, as cells 
are constantly subjected to endogenous and exogenous stress. # ese 
genetic alterations include many diff erent kinds of structural changes 
in DNA resulting from various types of damage to the purine and pyri-
midine bases, single- or double DNA-strand nicks and gaps, intrastrand 
or interstrand crosslinks and DNA-protein crosslinks 15. Most of these 
alterations are identifi ed and rectifi ed by the cellular surveillance systems 
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that include DNA-repair mechanisms and cell cycle checkpoint control. 
However, some changes are likely to persist, especially if the mutation 
rate is high, in which case the alterations can be carried on to the next 
generation of cells 15, 32. # e number of spontaneous mutations in human 
cells has been estimated to be around 10-8–10-10 per base pair per cell 
cycle, but in association with external exposure, the rate of mutations 
may rise by 10–1000 fold 32. 
# e sources of endogenous DNA damage include DNA-polymerase 
errors, oxidative stress from normal aerobic processes, and premutagenic 
DNA methylation 33–35. External factors consist of diff erent kinds of 
carcinogens and their active metabolites 15. # e mutations found in 
cancer vary from small changes in nucleotide sequences, such as point 
mutations, to changes in chromosome copy numbers or chromosomal 
alterations that aff ect long stretches of DNA such as translocations, dele-
tions or amplifi cations 22. In general, cancer cells are found to harbor a 
wide variety of alterations in their DNA 12, 27, 28.
Nucletiode changes in DNA sequence can be classifi ed as deletions, 
insertions or base substitutions, classifi ed either as transitions (change 
of a pyrimidine to another pyridimine or a purine to another purine) or 
transversions (change of a pyridimine to a purine or vice versa) 35. De-
pending on the eff ect, a mutation can be further classifi ed as a frameshift 
(deletion or insertion causing a shift in the translation reading frame), 
missense (a base substitution that changes the corresponding amino-acid 
to some other amino acid), nonsense (a base substitution that changes 
the amino-acid to a stop codon) or silent (a base substitution that does 
not change the amino acid) mutation. 
In particular, C to T base transitions arise spontaneously, especially 
at genomic sites where cytosine residues are methylated and the hydro-
lytic deamination of the pyrimidine may occur 33. Certain carcinogens 
appear to frequently cause specifi c kinds of mutations, which are then 
considered as a “carcinogen fi ngerprint” when studying the molecular 
etiology of cancer 15, 34. Nevertheless, the detection of a mutation in a 
cancer cell does not necessarily mean that the mutation is the primary 
origin of carcinogenesis. In many cases, mutations are believed to arise 
as by-products of transformation or they may have occurred before the 
clonal expansion 15. 
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Identifi cation of sequence changes is becoming increasingly important in 
the diagnosis of diff erent diseases as well as being useful in drug discovery 
and development. Traditional mutation detection methods analyse the 
DNA sequence either directly by techniques based on sequencing or 
probe hybridization, or indirectly by methods based on the analysis of 
sequence-dependent physico-chemical properties of DNA, like melting 
or folding 36. Recently, the advances in technology have made it possible 
to study whole cancer genomes using large scale and high-throughput 
DNA sequencing. It is now possible to detect almost any genomic altera-
tion in individual tumours and discover biologically signifi cant changes. 
On the other hand, the amount of data generated is enormous and data 
processing and statistical analysis become extremely important in the 
evaluation and interpretation of the results 27, 37, 38. 
Direct sequencing has long been considered as the “golden standard” 
for mutation analysis. It allows the identifi cation of the exact location and 
type of sequence change, but at the same time it is both quite expensive 
and time consuming 36. Various other methods traditionally based on 
gel electrophoresis have been used in mutation detection to separate 
the wildtype sequence from the mutated one. For example, denaturant 
gradient gel electrophoresis (DGGE) and single strand conformation 
polymorphism (SSCP) are two commonly used methods for mutation 
screening, both originally based on gel separation. SSCP and DGGE 
methods are especially useful when the location and type of alteration 
are not known, in other words, in screening for mutations.
In DGGE, a denaturing gradient is used to separate the homoduplexes 
(wild type-wild type or mutated-mutated) of DNA from heteroduplexes 
(wild type-mutated). Since the heteroduplexes are a combination of 
wild type and mutated DNA-strands, they have a lower stability than 
the homoduplexes. Due to the lower stability, they denature in a lower 
percentage of denaturant and can be separated from homoduplexes by 
electrophoresis 39, 40. In SSCP, the separation is based on diff erent elec-
trophoretic mobility of a sequence specifi c conformation of the single 
stranded DNA fragment 40, 41. # ese methods are simple to run and do 
not typically require large investments in equipment, but on the other 
hand they are not suitable for analyzing large numbers of samples, as 
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they are not easily automated. With the application of the capillary elec-
trophoresis (CE) technique, SSCP has become more readily applicable 
for investigating large collections of DNA samples 42. Ultimately, with 
mutation screening methods, the DNA fragments with alterations must 
be sequenced before the exact type and location of the altered sequence 
can be identifi ed. 
Analyzing paraffi  n embedded tissue (PET) samples has proven to be 
challenging, as fi xing the DNA by formaldehyde or some other agent 
causes damage that can impair PCR or result in polymerase errors 43. 
Taq polymerase has a tendency to insert adenosines when no template 
base is present, causing alterations, artifacts, that may get amplifi ed in 
the subsequent rounds of PCR 44. However, fi nding the exact same arti-
fact in a second independent PCR is very improbable 44. Furthermore, 
the sensitivity of sequencing has been shown to be lower as compared 
to mutation screening methods 45–48. Careful planning of the mutation 
analysis strategy is therefore extremely important while studying PET 
samples to ensure the validity of results. 
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# e protein encoded by TP53 tumour suppressor gene, the p53 tumour 
suppressor, was fi rst identifi ed in 1979 as a protein that was bound by SV40 
T-antigen in SV40 induced tumours 49. Early observations led to the belief 
that p53 might function as an oncogene; however, in the late 1980s the 
normal function of p53 was clarifi ed as being anti-oncogenic 50.
# e TP53 is commonly mutated in human cancer; somatic TP53 
mutations are found in about 50 % of human cancers 51, 52, and they are 
often associated with a loss of the second allele of the gene 34. It is gener-
ally believed that also in tumours that carry a wild-type TP53, the TP53 
pathway is inactivated by some other mechanism 52. # e elimination of 
p53 function is generally required in order to achieve resistance to apoptosis 
which is an important feature of most, if not all, types of cancer 14. 
A germline mutation of the TP53 gene is the most common reason 
for Li-Fraumeni syndrome, a familial cancer syndrome where the carriers 
of TP53 germline mutation are predisposed to a variety of tumours, and 
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90 % of the carriers are diagnosed with cancer by the age of 60 years 
16, 53.
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# e tumour suppressor TP53 gene is a single copy gene situated in human 
chromosome 17p13.1 34, 54. It is 20 kb long and contains 11 exons, with the 
fi rst exon and part of exon 11 being non-coding (Figure 1) 54. # e TP53 
DNA-sequence is highly conserved in vertebrates and it is small enough 
to be relatively easily analyzed 32, 34. TP53 belongs to a small family of 
related genes that includes two other members, p63 and p73. Although 
they all are structurally and functionally related; p63 and p73 have roles 
in normal development, whereas the main role of TP53 seems to be the 
prevention of malignant growth 55. Nevertheless, p53 also seems to play 
a role in the developmental process 56. Recently diff erent isoforms of 
p53 have been found. Some of them have been shown to be aberrantly 
expressed in tumours, however, the function and signifi cance of diff erent 
p53 isoforms remains still somewhat unclear 57.
Figure 1. The TP53 gene and protein. TP53 mutation distribution in human 
cancer (as described in the IARC database 58) and mutation hot spots are 
shown in relation to the exons and functional domains. Highly conserved 
regions are marked with darker shading. 
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TP53 encodes for a 53 kDa phosphoprotein that is expressed at very 
low levels in the nucleus of normal cells 34, 54; it is active as a homote-
tramer 59, 60. # e human p53 has 393 residues 59 and contains fi ve widely 
conserved areas (Figure 1) 54. # e protein can be divided into three 
diff erent parts: the amino-terminal containing transactivation domain 
and regulatory domains, the central region containing sequence-specifi c 
DNA-binding domain, and the multifunctional carboxy-terminal (Figure 
1) 50. 
# e amino-terminal (N-terminal) houses the transactivation domain 
(residues 1-63) that interacts with a number of regulatory proteins such 
as MDM2 and p300/CBP followed by the proline-rich region (residues 
64-92), which contains SH3-domain binding motifs and is thought to 
have a regulatory role (Figure 1) 59, 61.
# e central region (residues 94-292) is responsible for specifi c DNA-
binding, and it contains the most evolutionary conserved sequences of 
the protein (Figure 1) 52, 59, 61. In the homotetramer, p53 central regions 
form strong interactions with each other and co-operatively bind DNA. 
# ese interactions facilitate DNA bending as well as looping, which 
might be needed when binding to promoters where the p53-binding 
sites are not next to each other, for example, in the p53 target genes 
p21/WAF1/Cip1 and cyclin G 50. # e central region is also an important 
domain for specifi c protein-protein interactions 62.
Finally, the carboxy-terminal (C-terminal) includes the tetrameriza-
tion domain (residues 325-355), which regulates the oligomerization 
of p53 and the negative autoregulatory domain of the extreme carboxy-
terminus (363-393). # e latter contains acetylation and phosphorylation 
sites and regulates the DNA-binding activity of p53 (Figure 1) 59, 61. # e 
carboxyl terminal can also bind nonspecifi cally to diff erent kinds of 
DNA, including damaged DNA and reannealing complementary single 
strands of DNA or RNA 50.
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# e tumour suppressor protein, p53, plays a central role in a cell’s 
response to diff erent kinds of stress situations that include many of 
the events associated with cancer initiation and progression. # e p53 
induction is extremely sensitive to DNA damages (genotoxic stress), 
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such as those caused by cellular processes, exposure to diff erent kinds 
of chemical carcinogens or radiation. Many other signals also activate 
p53, including oncogene activation and various cellular stresses, such as 
the changes in temperature or the redox-equilibrium, telomere shortening, 
hypoxia and defi ciency of ribonucleotides 56, 63, 64. Generally, when activated, 
p53 mediates a broad spectrum of processes that suppress growth 64. # e 
diversity of cancer related signals that trigger the p53 response explains, 
at least in part, why the p53 pathway is inactivated in almost all types 
of cancer 63.
In normal non-stressed cells, p53 is maintained at very low steady-state 
levels. # e relatively few p53 molecules that exist appear to be rather ineff ec-
tive as transcription factors, even though they contribute to the maintenance 
of basal expression levels of several p53 target genes 63. Activation of p53 in 
response to stress involves a clear increase in the number of p53 molecules 
within the cell nucleus. # is is achieved by post-translational changes to 
protect p53 from degradation and thus enable the transcriptional activation 
of target genes. # e activity of p53 can also be controlled by the subcellular 
localization of p53 and other pathway components 55. 
It is known that p53 acts as a sequence-specifi c DNA-binding tran-
scription factor that can activate or repress the transcription of a large 
number of target genes 55, 60. # e DNA sequence found in the various 
p53 response elements contains a consensus sequence with similar ele-
ments, but it is not exactly the same for diff erent targets genes, and as a 
result p53 binds to diff erent sites with highly heterogeneous affi  nities 52. 
In addition to activation of genes with p53-binding sites, p53 is also 
capable of strongly inhibiting transcription of certain genes lacking 
p53-binding sites. Several genes, many with anti-apoptotic functions, 
have been identifi ed as in vivo targets of p53 repression 50, 55, 60. Tran-
scription independent activities of p53 that trigger apoptosis have also 
been described 55, 56. # ese mechanisms might involve direct binding of 
the Bcl-2 protein family members at the mitochondria and most likely, 
both transcription-dependent and -independent pathway cooperate and 
complement each other in the induction of apoptosis 65. 
Several cellular responses can be induced by p53, most importantly 
cell cycle arrest and apoptosis. # ere is also evidence that p53 plays a 
role in the regulation of glycolysis, autophagy, cell survival and oxidative 
stress, and is involved in cellular senescence, angiogenesis, diff erentiation, 
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repair of DNA-damage, invasion and motility, and bone remodelling. 
# e outcome of p53 activation depends on many factors that are both 
intrinsic and extrinsic to the cell 55, 56, 63. # e elimination of damaged, 
stressed or abnormally proliferating cells by p53 has been considered to 
be the principal means by which p53 inhibits tumour growth 66, but p53 
has also another important mechanism of reducing tumours. When deal-
ing with low levels of damage that are encountered during normal cellular 
life, p53 acts to reduce the levels of ROS and promotes DNA repair and 
survival of the slightly damaged cell to allow the repair to proceed 56, 62. On 
the other hand, inappropriate or prolonged activation of p53 in normal 
tissues can lead to tissue damage and it has been associated with multi-
ple sclerosis, neurodegenerative disorders and exacerbation of ischemic 
damage from stroke or cardiac arrest 66.
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TP53 mutations are found in most human cancers arising from a variety 
of tissues, whereas other important tumour suppressor genes (for example 
APC, WT1, or NF1) seem to have a more limited tissue variation 18, 34 
In addition, TP53 mutations are found in signifi cant frequency in hu-
man cancer, although the frequency varies from one cancer type to the 
next 34, 55, 67. Information about TP53 mutations in human cancer has 
been collected in databases 58, 68, which contain thousands of mutations. 
In certain cases the TP53 mutation spectrum appears to refl ect the DNA 
damage caused by a particular carcinogen, and these data may be useful 
in defi ning the molecular mechanisms responsible for carcinogenesis 32, 
51. # e frequency and type of TP53 mutations have also been suggested 
to help to evaluate the type and level of carcinogen exposure 32. Overall, 
the TP53 gene has many useful properties when studying carcinogenesis 
making the TP53 one of the most extensively studied genes in cancer 
research.
# e accumulation of p53 proteins altered by mutation in tumour 
cells can in principle have two consequences in carcinogenesis: i) a 
dominant negative role of the mutated allele by hetero-oligomerization 
with wild-type p53 expressed by the second allele, or ii) a specifi c gain 
of function of mutant p53 62, 69–71. In most cancer cells, TP53 mutations 
are present on only one allele, the other being either wild-type or lost, 
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indicating that the effi  ciency of dominant-negative inhibition might 
not be complete and probably depends on the type and location of the 
initial mutation 15, 34, 55, 69. All TP53 mutations are not equivalent and 
they display a marked variation in structure as well as in loss of func-
tion. While the mutations most often found in human cancers (the “hot 
spot” mutants, Figure 1) show total loss of transactivating capacity, other 
mutants may retain at least partial activity and still transactivate a subset 
of target genes, leading to a wide range of possible mutant activities 52. 
However, rare mutants seem to have still most, if not all, wild type TP53 
activity 72. # e TP53 mutants with only a partial loss of activity might 
require a second mutation in order to fully inactivate the protein. Since 
p53 functions as a tetramer, two weak mutations in two diff erent alleles 
could potentially lead to a fully inactive protein 72.
# e mutations selected in carcinogenesis aff ect the properties of p53 
that, when alterated, lead to increased tumorigenic potential of the cell 15, 50. 
Some TP53 mutants can be even considered oncogenes 55, 69. On the other 
hand, the biological eff ect of a total absence of TP53 due to a nonsense or 
frameshift mutation is most likely very diff erent 15, 34, 55, 69. Mouse models 
support the claims for the heterogeneity in response to diff erent kinds 
of TP53 mutations. Knock-out mice without TP53 display a diff erent 
spectrum of tumours than the knock-in mice with various TP53 hot spot 
mutants. In contrast to knock-out animals, the knock-in mice exhibit a 
higher frequency of solid tumours with a high potential for metastasis, 
as observed also in mice expressing one mutant allele in a TP53 null 
background. # is is one of the strongest arguments for a gain of func-
tion of mutant TP53 52, 62. 
In addition, numerous single nucleotide polymorphisms (SNPs) and 
other sequence variations are present at the TP53 locus. Most of these 
variations are found in introns and probably do not have any signifi cant 
role in carcinogenesis. So far, the majority of TP53 polymorphisms has 
not been assessed for altered function or increased susceptibility to cancer. 
Only for two of these SNPs (P47S and R72P) is there suffi  cient molecular 
evidence to suggest a functional change in the p53 pathway attributable 
to the polymorphism 73. However, there are no studies with large enough 
populations to report clearly signifi cant associations between altered 
cancer risk and TP53 polymorphisms and the molecular models have 
been based mainly on in vitro studies with cell lines 73.
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# e mutations in cancer are scattered along the TP53 gene (Figure 1), and 
occur also at the splice junctions 15, 34. # ree hundred of the 393 codons 
in the TP53 gene have been reported to be mutated in human cancer 34. 
Nonetheless, according to the available data, only about 5 % of TP53 
mutations appear to be in the regulatory domains (amino terminal and 
carboxyl terminal), whereas most of the TP53 missense mutations are 
clustered in the central part, particularly within four highly conserved 
regions (Figure 1) 50, 55. Each codon in the central region has been re-
ported as being mutated, while the mutation rates range from two cases 
for infrequent mutations to more than 1000 for hot spot mutations, 
which occur in codons 175, 245, 248, 249, 273 and 282 (Figure 1) 15, 
52, 55, 62. # ese hot spot codons contain about 30 % of all reported muta-
tions 15, 55. # e distribution of mutations cannot be explained only by 
factors related to acquisition of mutations; hence, other mechanisms, in 
particular preferential repair or choice of inactivating or gain-of-function 
mutants, may infl uence the selection of mutants in cancer tissue. It is 
commonly assumed that inactivation of the apoptotic activity is the main 
target of TP53 gene mutations 62.
Unlike most other tumour suppressor genes (such as RB or APC gene) 
that are inactivated by frameshift or nonsense mutations leading to the 
formation of unstable or truncated protein, the most common TP53 
mutation type found in tumours is a missense mutation caused by a single 
amino-acid substitution. About 80 % of the TP53 mutations described 
so far are of this type (Figure 2) 15, 31, 32, 55, 62, 69, 70. Most TP53 missense 
mutations lead to a synthesis of stable protein that has lost totally or 
partially its the transcription capabilities and accumulates in the nucleus 
of tumour cells 62, 69. As common a predominance of missense mutations 
occurs in oncogenes such as KRAS 15. In general, the missense mutations 
seem to be the most frequent genetic alterations in the coding sequence 
of human cancer genome (excluding large genomic rearrangements) and 
the distribution of TP53 mutation types in cancer closely resembles this 
overall distribution of mutation types in cancer in all genes 28, 62, 74. Con-
sequently, the distribution of TP53 mutation types does not necessarily 
reveal any specifi c biological function, but refl ects the importance of the 
p53 central region structure for DNA-binding; even small modifi cations 
in this region can lead to a loss of p53 transcriptional activity 62. 
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Figure 2. The general TP53 mutation profi le by type of mutation and base 
substitution in human cancer according to the IARC database R13 58.
Transitions are more frequent than transversions among TP53 mis-
sense mutations and they occur particularly often at CpG sites, (Figure 
2). # e frequent methylation of the C residues, which can potentially 
lead to deamination of 5-methylcytosine to thymine (T), is assumed to 
be the reason for a C to T transition in these sites 75–77. Although the 
majority of TP53 alterations are missense mutations, there are also 8 % 
of nonsense mutations and 9 % of small deletions or insertions (Figure 
2) 32, 62. It is noteworthy that these types of mutations occur more fre-
quently outside the central region (they represent 54 % of the mutations 
in exons 2–4 and 77 % of those in exons 9–11 32) as compared to the 
central region (they represent 20 % of the mutations found in exons 
5–8) 32, 62. # is might be explained with the observation from functional 
analysis of missense mutations outside the central region showing that 
the transcriptional activity of p53 is not severely impaired by one mis-
sense mutation and that at least two independent point mutations are 
required to inactivate the transcriptional activity 15, 62. In addition to the 
other mutation types, about 4 % of TP53 mutations are silent (Figure 
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2). # ese silent mutations may be passenger mutations co-selected with 
another mutation in TP53 62. 
A number of specifi c TP53 mutational events have been recognized 
in diff erent types of human cancer. # e best known examples of mo-
lecular linkages between exposure to carcinogens and TP53 mutations in 
cancer are the correlation of exposure to UV light with tandem double 
CC>TT transition mutations at dipyrimidine sites in skin cancer, the 
correlation of dietary afl atoxin B1 exposure with G to T transversion at 
codon 249 of TP53 in hepatocellular carcinoma and the correlation of 
exposure to cigarette smoke with G to T transversion in lung carcinomas 
15, 32, 51, 69, 78. 
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Infl ammation is a well-coordinated physiological process that occurs 
after various kinds of cellular and tissue damage. It can be caused by 
microbial pathogen infection, chemical irritation, wounding, and/or 
endogenous injury 79, and it is normally self-limiting. Infl ammation may 
be related to tumorigenesis in three ways: (i) acute infl ammation can 
contribute to the regression of cancer 79–82, (ii) certain chronic infl amma-
tory conditions, such as infl ammatory bowel disease, ulcerative colitis, 
haemochromatosis and viral hepatitis 23, 81, 83, 84 can increase cancer risk, 
and (iii) oncogenic mutations, for example mutations in RAS, MYC 
and RET, may evoke infl ammation since various types of oncogenes 
promote cellular infl ammatory transcriptional programs, for example 
the induction of angiogenesis 23, 81.
During the injury associated with tissue wounding, cell proliferation 
is enhanced while the tissue regenerates, but both proliferation and in-
fl ammation should cease after the repair is completed 85. If the control 
of infl ammatory components fails, acute infl ammation can convert to 
chronic infl ammation, and generate a pathologically conducive microen-
vironment as the infl ammatory cells produce a great amount of growth 
factors, cytokines, and reactive oxygen and nitrogen species (ROS and 
RNS, respectively) 79, 80, 83. In chronic infl ammation, continued tissue 
damage is sustained, which in turn induces cell proliferation 79, 80. # is 
is likely not a direct cause of cancer, but incessant cell proliferation in 
28
9)-%#"%:)60)!1%)&"!%-+!8-%
an environment fi lled with infl ammatory cells, growth factors, activated 
stroma, and DNA-damage promoting agents can predispose to carcino-
genesis 79, 85. # e continual tissue damage and regeneration of tissue in 
the presence of highly reactive nitrogen and oxygen species can result in 
permanent genomic alterations, when these free radicals interact with 
the DNA of proliferating cells 85. In line with this, patients with chronic 
infl ammatory diseases have been shown to exhibit alterations in cancer-
related genes and proteins 83. For example, in rheumatoid arthritis, muta-
tions in the tumour suppressor gene TP53 are seen at frequencies similar 
to those occurring in tumours 86. In addition, irrespective of the cause 
of the cancer initiation, infl ammatory cells and mediators are present in 
the microenvironment of most, if not all, tumours 81. It has been stated 
that “in a sense, tumours act as wounds that fail to heal” 85, 87.
In epidemiological studies a link has been demonstrated between 
chronic infl ammation and various types of cancer, including bladder, 
cervical, gastric, intestinal, lung, oesophageal, ovarian, prostate and 
thyroid cancer 79, 81, 88. It has been estimated that underlying infections 
and infl ammatory mechanisms play a role in about 15–20 % of all 
global cancer deaths 81, 85. Furthermore, treatment with non-steroidal 
anti-infl ammatory drugs, such as acetylsalicylic acid (aspirin), that 
inhibit cyclooxygenase-enzymes (COX-1 and COX-2) has been shown 
to decrease the incidence and mortality of several tumour types 81. In 
addition, targeting of infl ammatory cells, the mediators of infl ammation 
(chemokines and cytokines, for example TNF-? and IL-1?) or the key 
transcription factors involved in infl ammation (for example NF-?B and 
STAT3), decreases the incidence and spread of cancer 81. 
MNVN;.=R2*$$"RQ(1+%()M.W=CX)MY
Cyclooxygenase (COX) enzymes catalyze the conversion of arachidonic 
acid to thromboxanes and prostaglandins, the key mediators of infl am-
mation 79, 89, 90. # ere are two isoforms, COX-1 and COX-2, which share 
about 60 % amino acid identity 90, 91. Although there are some exceptions, 
in general COX-1 is constitutively expressed and responsible for the basal 
prostaglandin synthesis 89, 91. In contrast, COX-2 is rarely expressed in 
normal tissues but its expression can be induced by many physiological 
and stress-related signals including growth factors, cytokines and other 
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mediators of infl ammation, tumour promoters, oxidizing agents and 
DNA damaging agents 89, 92. # e distinct prostaglandin(s) synthesized 
as the result of COX-2 induction depends on the tissue, availability of 
substrates and the specifi c synthase enzymes present in the cell 89. # e 
regulation of COX-2 gene takes place mainly at the transcription level 
and several infl ammatory factors regulate COX-2 by directly activating 
its promoter 84, 91. Many of the signals that activate COX-2 also induce 
tumour suppressor p53 84. 
# ere is considerable evidence from molecular, pharmacological and 
clinical studies to link COX-2 with the development of cancer. Increased 
amounts of COX-2 are found commonly in both premalignant and 
malignant tissues and the elevated COX-2 expression has been reported 
in many cancers, for example in lung cancer 93, colon cancer 94, pancre-
atic cancer 95 and stomach cancer 96. In general, COX-2 expression is 
higher in well-to-moderately diff erentiated tumours and in metastasis 
compared to poorly diff erentiated tumours 84. Inhibitors of COX, such 
as acetylsalicylic acid or other non-steroidal anti-infl ammatory drugs, 
have been shown to reduce the incidence of diff erent malignancies 84, 93, 
97–99. An inverse relationship between COX-2 overexpression and survival 
of cancer patients has also been reported in retrospective studies 84, 100, 
101. Overall, the COX-2 expression may not be the driving force for the 
carcinogenesis but rather it appears to play a role in enhancing cancer 
development in the overall context of chronic infl ammation 79.
Interactions between COX-2 and tumour suppressor p53 have 
been shown in vitro and in vivo, but the results have been contradic-
tory. It has been shown that p53 can upregulate COX-2 92, 102, 103, but 
it can also suppress the transcription of COX-2 98, 104. Additionally, 
COX-2 has been observed to exhibit strong inhibitory eff ects on p53 
transcriptional activity 102, 103. As proposed in the recent publication of 
de Moraes et al 84, these diff erent results might be explained by two dif-
ferent mechanistic scenarios, where the variable patterns of interaction 
between COX-2 and p53 depend largely on the infl ammatory context. 
In infl ammation-derived tumours, NF-?B and p53 can co-operate to 
induce COX-2, whereas in non-infl ammatory tumours, p53 does not 
appear to participate in the activation of COX-2 and in those cases, TP53 
gene mutations would act as an independent factor in the tumorigenesis 
84. In addition, a correlation between COX-2 expression and TP53 
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wild type status has been found in adenocarcinoma but not in SCC of 
Barrett's esophagus 92. # is suggests that the participation of p53 in the 
regulation of COX-2 expression may also be tissue specifi c. 
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Cancer of the nose and paranasal sinuses (ICD-7 code 160, except 160.1, 
corresponding to ICD-10 code C30.0, C31) is a rare form of cancer, 
with an incidence of 0.5 to 1.5 new cases per year per 100 000 in men 
and 0.1 to 0.6 per 100 000 in women 9, 105. # e incidence of sinonasal 
cancer varies markedly between diff erent countries and even within 
the same country. # is variation has not been attributed to individual 
susceptibility, such as genetic diff erences, but is most likely due to dif-
ferences in exposure 9, 105. 
# e main histological types of sinonasal cancer are adenocarcinoma 
and squamous cell carcinoma (SCC) 106. # e most common form is 
the squamous cell carcinoma; only 4–20 % of sinonasal tumours are 
adenocarcinomas, though adenocarcinoma is the histological type more 
strongly associated with wood dust exposure 107. Sinonasal adenocarcino-
mas are well characterized morphologically by the presence of neoplastic 
glandular structures that arise in the nasal cavity and paranasal sinuses 
and they are located mainly in the ethmoid sinus and the upper part of 
the nasal cavity. Local recurrence is the most common cause of death 
among patients with sinonasal adenocarcioma; the average 5-year survival 
is 20–50 % 108. Distant and lymph node metastases are rare (5–10 % of 
all cases) 107. A fraction of sinonasal adenocarcinomas are classifi ed as the 
intestinal type adenocarcinoma, based on their close histopathological 
resemblence to adenocarcinoma of the colon 109.
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# e fi rst evidence for the extremely high risk ratios associating wood-
dust exposure and sinonasal cancer came from the UK, and subsequently 
numerous epidemiological studies have confi rmed this association 9. Very 
high relative risks have been invariably found and 10–45-fold risks have 
been indicated for the adenocarcinoma cell type in association to occu-
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pational exposure to hardwood dust. # e risk related to softwood dust 
exposure is less clear 8–10, 110, 111. Another risk factor for sinonasal cancer 
suggested by the epidemiological studies is cigarette smoking, with a two- 
or threefold increased risk of nasal cancer observed among smokers and a 
reduction in risk among long-term quitters. # is eff ect may, however, be 
limited to the squamous cell carcinoma rather than adenocarcinoma 112, 
113. Other risk factors for sinonasal cancer include occupational exposure 
to textile or leather dust, to chromium (VI) compounds, to nickel and 
its organic compounds and possibly to formaldehyde, but so far the 
published studies on these exposures are partially confl icting 114.
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Exposure to wood dust in the occupational setting is a common oc-
currence. It has been estimated that in the years 2000–2003 about 3.6 
million workers (approximately 2.0 % of the working population) were 
occupationally exposed to inhalable wood dust in the European Union 
115 and over half a million of these workers were estimated to be exposed 
to high levels (exceeding 5 mg/m3) of wood dust 115. Roughly two-thirds 
of the wood used commercially is softwood, but the wood species used 
vary regionally and also depending of the type of product being manu-
factured. In general, the terms “hardwood” and “softwood” refer to the 
taxonomic categorization of trees and not necessarily to the hardness of 
the wood. Gymnosperms or conifers are referred to as hardwoods while 
angiosperms or deciduous trees represent softwoods 9. While hardwoods 
are generally denser than softwoods, the density varies considerably 
within each family. Mixed exposure to dusts from more than one spe-
cies of wood and to dusts from wooden boards typically occurs in most 
branches of the wood-working industries 9, 115. 
Wood dust is a complex mixture of compounds including a wide 
variety of biologically active substances, also genotoxic and carcinogenic 
compounds 9, 110. Chemically, it is a mixture of organic and inorganic 
components while the composition varies according to tree species 9, 110. 
# e particulate nature of the wood-dust exposure also plays a role in 
generating ROS within cells and inducing DNA damage and evoking 
an infl ammatory response 9, 110, 116–119. Asthma has been linked with oc-
cupational wood dust exposure by epidemiological studies 120, further 
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demonstrating the connection between infl ammation and wood dust 
exposure.
Sinonasal cancer, especially adenocarcinoma, is strongly associated 
with occupational wood-dust exposure, as reported in many epidemio-
logical studies 9. Furthermore, some, though not all, studies have found 
elevated risks in association with wood dust exposure for other types 
of cancer, including lung cancer 9, 121–124. Consequently, wood dusts, 
in particular those originating from a variety of hardwood species, are 
classifi ed as carcinogenic to humans 9, 110, 124. 
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Multiple mechanisms of carcinogenesis have been proposed to be in-
volved in the development of sinonasal cancer related to wood-dust 
exposure, but there is very little experimental or human data in the 
literature. # e published fi ndings have been based on a relatively limited 
number of cases, mostly involving adenocarcinomas. In these studies, 
high frequencies of DNA copy number changes as detected by compara-
tive genomic hybridization have been detected 125, 126, while the mutation 
rates reported for the KRAS gene 127–132 and the TP53 tumour suppressor 
gene have been lower 131, 133–135. Initially, KRAS and HRAS mutations 
were found to be quite frequent in sinonasal cancer, with implications 
for histogenetic and prognostic signifi cance 128–132, but recent results 
show that tumours with KRAS mutations might represent only a small 
proportion of all sinonasal cancers 127. 
Infl ammation has also been proposed to play a signifi cant role in 
sinonasal carcinogenesis. Epidemiologic studies have suggested that 
environmental factors or infl ammation, for example chronic sinusitis 
or human papilloma virus infection, may represent etiologic factors in 
the induction of maxillary sinus carcinoma 133. # ere are also consist-
ent reports of impaired mucociliary clearance and mucosal alterations 
encountered during chronic wood-dust exposure 9. Mucosal alterations 
include dysplasia and metaplasia of the columnar epithelium, and to a 
lesser extent, changes in the squamous epithelium 9, 120. 
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At present, there are only a few studies that have studied TP53 muta-
tions in sinonasal cancer (Table 1). Most of them have concentrated on 
cancers of the intestinal type of adenocarcinoma, and the numbers of 
cases studied have been rather low. In these studies, a variable occurrence 
of TP53 mutations has been reported (18–60%) 131, 133–135. Some of the 
studies have also examined the accumulation of p53 in the cell nucleus 
in adenocarcinoma type of sinonasal cancer (Table 1). # e accumulation 
of p53 may refl ect a TP53 mutation, but other reasons for p53 accumu-
lation are also known; furthermore, not all mutations induce nuclear 
accumulation of p53. # e results reported indicate that p53 accumula-
tion is a common feature in adenocarcinomas, with immunopositivity 
ranging between 20–80% 132, 135, 136. 
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Lung cancer is the leading cause of cancer death with over 1 million 
deaths each year worldwide 5, 17, 140. It is the primary preventable type 
of cancer since tobacco smoking is the cause for most lung cancers 5, 141, 
142. # e association between smoking and lung cancer is well established 
with a 10- to 20-fold increased occurrence of lung cancer in smokers 
compared to never smokers 5, 112, 143. Duration of smoking and number 
of cigarettes smoked are the strongest determinants of the lung cancer 
occurrence in smokers, both showing positive proportionality 88. Nev-
ertheless, it has been estimated that about 10–15 % of all lung cancers 
in men and about 50 % in women are not attributable to active tobacco 
smoking, which overall accounts for 25 % of all lung cancers worldwide 
5. # e known environmental risk factors for lung cancer are second 
hand tobacco smoke, asbestos, radon, chromium, arsenic, cadmium, 
silica and nickel, as well as outdoor air pollutants. In addition, previous 
lung disease and genetic, hormonal, viral and dietary factors have been 
implicated 5, 140, 143. In Western countries (North America, Western and 
Northern Europe, Australia), the lung cancer incidence has stabilized 
over the past decades, especially among men 5, 112, 140. In contrast, the 
lung cancer incidence among women and in the developing countries 
is still increasing 5, 112.
Lung cancers are classifi ed into four major histological types; ad-
ditionally multiple minor or rare forms exist. # e main types are the 
small cell lung cancer (SCLC) and the three non-small-cell lung cancers 
(NSCLCs): squamous cell carcinoma (SCC), adenocarcinoma and large 
cell carcinoma 5, 140. Tobacco smoking is associated with all histological 
types of lung cancer with varying strength of association and there is 
good scientifi c evidence indicating multiple smoking-related mechanisms 
of lung carcinogenesis 5, 88, 112, 144. Small cell lung carcinoma has the 
strongest association with smoking 5, 141, 144. With respect to non-small 
cell lung carcinomas, smokers have most commonly had squamous cell 
carcinomas. However, over time, there has been a shift in the distribu-
tion of the major histological types observed in lung cancer. Globally, the 
incidence of squamous cell carcinoma is decreasing while the incidence 
of adenocarcinoma is increasing. # is is most likely a result of changes 
in cigarette design and composition 5, 88, 140. # e benzo[a]pyrene content 
37
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of cigarettes has decreased by about 60 % whereas the formation of nit-
rosamines during tobacco storage, processing and smoking has increased 
following the changes in the nitrate content in blends of tobacco 5, 88, 140. 
Nitrosamines, such as nicotine-derived nitrosaminoketone (NKK), are 
potent lung carcinogens that induce adenocarcinomas in experimental 
animals 5, 88, 140, 145, 146. In addition, the lower nicotine content may cause 
deeper inhalation when smoking to compensate for the reduced nicotine 
content and the smoke inhaled deeper may penetrate to more peripheral 
parts of the bronchi 88. For never smokers, adenocarcinoma is the most 
common histological type 5, 141, 144.
Common genetic changes in all histological types of lung cancer 
include mutations in TP53, defects in the p16INK4/RB pathway, loss of 
heterozygosity at alleles on chromosome 3p 15, 144 and inactication of 
LKB1 147. Mutually exclusive mutations at codon 12 in KRAS or in the 
tyrosine kinase domain of the EGFR have been found in about 30 % 
of adenocarcinomas but are rare in other histological types 15, 144. # ere 
are also indications that cigarette smoking evokes chronic infl ammation 
that is associated with the development of lung cancer 148.
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Smoking is a major cause of disease and mortality that could be prevented 
88, 112. # ere are about 1.3 billion smokers globally and approximately 
150 million deaths related to tobacco use are projected for the years 
2000–2024 if there is no change in current smoking patterns. In the 
more developed countries, smoking is involved in over 30 % of all can-
cer deaths 15, 88, 149. Cigarette smoke contains several thousand chemicals 
including over 60 identifi ed as carcinogens by IARC 5, 145, 149, 150. # ese 
include potent carcinogens like the polycyclic aromatic hydrocarbons 
(PAHs) and the nicotine-derived nitrosamine ketones (NKK and NNN) 
but also aldehydes and other volatile organic compounds such as benzene 
and butadiene are present 5, 88, 112, 145, 149. Metabolites of the tobacco smoke 
carcinogens are able to bind covalently to DNA, often at certain specifi c 
sites, and form bulky adducts. # ese bulky adducts can be removed by 
DNA repair such as the nucleotide excision repair system, of they may 
lead to apoptosis. If they persist, bulky adducts can result in mutations 
that potentially could initiate or promote carcinogenesis. Since the ad-
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duct formation and persistence plays a important role in carcinogenesis, 
the balance between activation, detoxifi cation and DNA repair of these 
lesions is a signifi cant factor in determining individual susceptibility to 
cancer 5, 149.
As mentioned, smoking displays a well-established causal relation-
ship with lung cancer and also involuntary or secondhand smoke is a 
risk factor 5, 88, 112, 151. In addition to lung cancer, tobacco smoking is 
an important causal factor for oral, otopharyngeal, hypopharyngeal, 
laryngeal, and oesophageal cancers as well as those of pancreas, bladder, 
and renal pelvis. Smoking has also been associated with the cancers of 
the nose, stomach, liver, colon, renal body, and cervix and with myeloid 
leukaemia 112, 149, 152. # e increased cancer risk induced by smoking rap-
idly declines after quitting. # e benefi t of stopping smoking is evident 
within fi ve years and it progressively becomes more marked with time, 
the risk remaining, however, higher than among non-smokers 2, 153, 154. 
In addition to cancer, tobacco use contributes also to other serious dis-
orders: cardiovascular disease, cerebrovascular disease, peripheral vascular 
disorders, abdominal aortic aneurysm, chronic obstructive pulmonary 
diseases and fetal disorders 88, 154.
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Lung cancer is known to frequently harbour TP53 mutations, with 
an overall frequency of about 50 %. # ey are more common in small 
cell and squamous cell carcinomas than in adenocarcinomas 140. # e 
frequency of mutations is higher in smokers (50–80 %) than in non-
smokers (10–28%) 15, 144, 150 and the occurrence of TP53 mutations in 
lung cancer from smokers has been shown to be associated with lifetime 
cigarette consumption and duration of smoking 150. 
# e TP53 mutation spectrum is diff erent between smokers and 
non-smokers 150, 155. An overrepresentation of G to T transversion muta-
tions in lung tumours in smokers has been observed in many studies 15, 
51, 150. # ese transversions often occur at TP53 codons 157, 158, 245, 
248 and 273 in smokers while underpresented in non-smokers 15, 51, 144, 
155. Mutations at codon 157 are also detectable in histologically normal 
lung tissue adjacent to cancer growth in smokers as well as in the lungs 
of smokers without cancer 51, 144. In vitro studies have demonstrated that 
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BPDE, the metabolically activated form of benzo[a]pyrene, and some 
other carcinogenic PAHs from cigarette smoke bind to guanosine resi-
dues at these hot spot codons 51, 144, 150. # ere is a concordance between 
the distribution of TP53 mutations in lung cancer in smokers and the 
experimental spectrum of DNA-adducts induced by PAH metabolites in 
the TP53 15. A higher proportion of G to T transversions (30 %) is also 
a characteristic diff erence in the mutation spectra between lung cancer 
and most other types of human cancers (frequency of G to T transver-
sions about 10 %) 15, 51, 144, 150.
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# e focus of this PhD-study was on TP53 mutations in sinonasal and 
lung cancer and their associations with the major causative exposures in 
these two cancer types, i.e. work-related wood dust exposure and tobacco 
smoking, respectively. An increased knowledge on the molecular mecha-
nisms in cancer associated with carcinogenic exposures is needed for risk 
assessment and prevention, especially with respect to sinonasal cancer 
related to wood-dust exposure, for which the current data are sparse.
# e specifi c aims were:
–  To compare CE-SSCP, DGGE and direct sequencing to fi nd out the 
benefi ts and relative sensitivities of the three methods for detection of 
somatic mutations of the TP53 gene in larger series of human tumour 
samples.
–  To study the frequency of TP53 mutations in sinonasal cancer and 
lung cancer populations with detailed exposure data available for 
molecular epidemiology analysis.
–  To study association between the TP53 mutation profi le and tobacco 
smoke-induced primary DNA damage in a lung cancer population 
of moderate to heavy smokers.
–  To analyze the TP53 mutation profi le in sinonasal cancer and to 
examine the relations between exposures and the discovered muta-
tion profi le. In addition, to compare the mutation profi le detected in 
sinonasal cancer to known data from other cancers available in large 
international databases 58, 68.
–  To explore cancer-related infl ammation by analyzing the expression 
of an infl ammation-related enzyme, COX-2, in sinonasal cancer.
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Lung cancer cases (n = 20) that were a subset of an earlier study 156 were 
analyzed for TP53 mutations. In this study, new DNA-samples were 
extracted from paraffi  n-embedded tissue (PET) samples of lung cancer, 
in order to ensure that all the samples were treated the same way and 
that there was enough DNA for the analysis. # is was not possible for 
few cases (T174, T182, T213, T246, and T316), for which DNA but no 
tumour specimens were available. In these cases, the DNA extracted in 
the earlier study was used. Samples were analyzed under dummy codes 
so that the TP53 mutation status was not known.
VN;NM.?$*(2&*+'.2/+1Q(%.61.%61$1+%+*.2+12('.. . .
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Paraffi  n-embedded tissue samples of sinonasal cancer tumours were col-
lected from three European countries (Denmark, Finland and France) 
(Figure 3) (II, IV). All incident cases of the cancer of the nose and 
paranasal sinuses (ICD-7 code 160, except 160.1, corresponding to 
ICD-10 code C30.0, C31) were identifi ed from the nationwide cancer 
registries in Denmark for the years 1991–2001, as described elsewhere 
127, and in Finland for 1989–2002 (II, IV). In Finland, every other case 
of squamous cell carcinoma (SCC) was randomly included. Informed 
consent was obtained for patients still living. In the case of the patient 
was deceased, the permission was received from the appropriate national 
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authorities (II, IV). # e archival formalin fi xed paraffi  n embedded tissue 
samples were collected from pathology laboratories. In France, cases were 
identifi ed in the regional cancer registries of Isère, Somme and Doubs 
for the years 1990–2002. # e tissue fi xation medium used in pathol-
ogy laboratories was often other than formalin (Bouin, which makes 
DNA-based molecular analyses diffi  cult to perform), resulting in a more 
restricted collection of paraffi  n embedded tissue samples (II, IV). # e 
study was approved by the appropriate national and institutional Ethics 
Review Boards in Finland, Denmark and France. 
Figure 3. Tumour collection in the sinonasal cancer study. Initially cancer reg-
istries in Denmark, Finland and France were contacted to acquire informa-
tion on sinonasal cancer patients. After the selection based on the medical 
records, the tumour sections from eligible cases were reviewed by a pathol-
ogy panel, which resulted in the fi nal collection of 358 histologically verifi ed 
sinonasal cancers.
Cancer registries
Denmark
211 cases
Finland
133 cases
France
88 cases
358 sinonasal cancer cases
432 sinonasal cancer cases
Selection based on
medical records
Histology review
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A panel of three pathologists reviewed tumour sections for the entire 
tumour collection (432 cases, Figure 3) without reference to the clinical 
details, exposure background or mutation status. Common criteria for 
inclusion and exclusion were established as presented earlier 127 (II, IV). 
In brief, tumours were included that corresponded to one of the main 
histopathologic categories of cancer of the nose and paranasal cavities as 
indicated in the WHO classifi cation of tumours 127, 157. Benign tumours, 
metastatic lesions and malignant tumours outside of these categories 
were excluded, as were cases that were miscoded in the registries. # e 
latter included, for example, intranasal melanomas, skin cancers, olfac-
tory neuroblastomas and adenoid cystic carcinomas. When appropri-
ate, immunohistochemistry was used to confi rm the tumour type in 
the excluded cases. A common reason for exclusion was location of the 
tumour in the vestibulum nasi or in the nasopharynx. In addition, some 
cases were not included in the study due to missing pathology reports, 
inadequate hospital records, poor condition of tissue sample or poor 
yield of DNA from paraffi  n-embedded tissue. # e fi nal collection for 
the molecular analysis consisted of 358 sinonasal cancer cases (170 cases 
from Denmark, 109 cases from Finland, and 79 cases from France), each 
case with a consensus histology diagnosis of adenocarcinoma, squamous 
cell carcinoma, or carcinoma not otherwise specifi ed (NOS) (II, IV). 
Demographic and other data for the cases included are reported in IV, 
Table 1. In the series under study, squamous cell carcinoma was the 
most common tumour histology (59 %, 213/358), followed by adeno-
carcinoma (34 %, 122/358) and carcinoma NOS (6 %, 23/358). With 
respect to the adenocarcinomas, 88 out of 122 (72 %) fulfi lled the WHO 
criteria 157 for intestinal type of adenocarcinoma and 92 % (81/88) of 
this type of tumour were in males (II, IV). 
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A series of cases with adenocarcinoma (n = 67) and squamous cell car-
cinoma (SCC; n = 37), the two major histological types of lung cancer, 
were selected from a Hungarian study population comprising various 
histological types of lung cancer. # e sample set consisted of 104 cases, 
42 females and 62 males, who underwent lung resection for primary 
lung cancer (III). After the selection for histology, there was no additional 
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selection for smoking status. # e samples of lung tumour and histologi-
cally non-tumorous peripheral lung tissue were gathered after obtaining 
informed consent. Information on smoking history was provided by the 
patients via self-reporting. # ree major smoking categories were defi ned 
as follows: (i) smokers, that included current smokers who smoked up to 
the time of surgery, and those patients who had quit smoking within one 
year before the surgery; (ii) former smokers who had given up smoking 
more than one year before the surgery, and (iii) never smokers (III). 
VNM. !"#$%&'(.\+29Q'$&1-.61.%61$1+%+*.. .
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In all study centers, patients or next-of-kin (preferably the last spouse 
or a child) of the deceased patients were interviewed by telephone in 
Denmark and Finland. In France, personal interviews were done and 
both techniques utilized a structured questionnaire designed for this 
study. # e interviews provided data on demographics, tobacco use, 
and employment histories, including occupational exposure to wood 
dust, formaldehyde, chromium (VI) compounds, nickel and its organic 
compounds, and textile and leather dust. Interview data was received in 
84 (49 %) of the Danish cases, 69 (63 %) of the Finnish cases and 51 
(65 %) of the French cases. In Denmark and Finland, the information 
obtained via the interviews on lifelong employment history was supple-
mented with data from additional sources. First, employer records were 
retrieved from the Danish National Pension Fund (Danish cases) and 
the Finnish Centre for Pensions (Finnish cases). # ese registries record 
employment histories for all companies; if a person has been employed, 
the working history and period of employment can be retrieved back to 
1964 in Denmark and to 1963 in Finland. In Denmark, the commercial 
classifi cation of each company was obtained from Statistics Denmark, 
and in Finland, the companies were classifi ed by an industrial hygienist 
according to an extended version of International Standard Industrial 
Classifi cation of all economic activities in 1990. Finally, job titles of the 
subjects were extracted from the Central Person Registry in Denmark 
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(data available since 1968) and from Statistics Finland (data available at 
fi ve-year intervals; retrieved for 1970, 1975, 1980, 1985 and 1990). In 
all, data on wood dust exposure was available for 79% (283/358) of the 
cases, on other occupational exposures, including formaldehyde, chro-
mium compounds, nickel and its organic compounds, and textile and 
leather dust (with some overlap in exposures), for 59 % (210/238) of the 
cases, and on smoking for 56 % (201/358) of the cases (II, IV, V). 
VNMNM.!"#$%&'(.+%%(%%0(1,
For each case, exposure to wood dust and to other risk factors of sinonasal 
cancers as listed above was assessed based on the entire work history by 
an experienced industrial hygienist in each study center. # e criteria and 
procedure for exposure assessment were harmonized between the study 
centers in a common meeting where each rater assessed exposures of 
fi ve cases, in order to minimize variation of exposure estimates between 
the assessors. # ere was also a discussion about diff erences in exposure 
characteristics between the countries and these were taken into account in 
the deliberation. Wood dust exposure estimates were subdivided by wood 
species and products used (soft wood, hard wood, wooden boards). # e 
industrial hygienists involved in the exposure assessment were blinded 
to the results of the mutation analysis (II, IV, V).
In Finland and in France, for each job held by a patient, the concen-
tration of exposure to wood dust was assessed by the industrial hygienists 
into six categories: unexposed, very low (<0.3 mg/m3), low (0.3–<1 mg/
m3), medium 1 (1–<2 mg/m3), medium 2 (2–<5), or high (≥5 mg/m3). 
Quantitative values (midpoints of the intervals) were assigned to each 
category of concentration. # e frequency of exposure (proportion of 
working time during which exposure occurred) was assessed separately. 
A level of exposure was then calculated for each job by multiplying the 
concentration by the frequency. # e classifi cation of exposure levels was 
based on data available in Finland and France 158, 159 and on exposure 
estimates generated for the EU member states in another arm of the 
larger study program to which this study also belonged 115. In Denmark, 
exposure levels were estimated by measurements of inhalable wood dust 
concentrations conducted in diff erent Danish woodprocessing industries 
in the 1990’s. A 6 % yearly decline as compared to the level in 1990 
46
;)'+!%-"+&$)+/7)'%!167$
was assumed for the years 1975–1990 and exposures were assumed to 
be constant before the year 1975. # is assumption was based on a large 
number of random measurements in the Danish wood industry taken 
from 1985 to 2003 160, 161. # ese showed a quite consistent a 6–7 % 
yearly decline. In line with this, a 7 % yearly decline has been reported 
from 1978 to 1997 for the US wood industry 162. Exposure level esti-
mates were also adjusted based on the average working distance from 
the exposure source (II, IV, V).
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DNA was extracted from frozen or paraffi  n embedded tissue (PET) sam-
ples using a standard phenol-chloroform extraction protocol. Extracted 
DNA was stored in aliquots of 100 µm/ml concentration at -20°C. For 
PCR amplifi cation of the gene sequences under study, 100 ng of genomic 
DNA was used in a 25 µl reaction, with the reaction carried out accord-
ing to the instructions of the manufacturer of the enzyme (TaqGold, 
Applied Biosystems) (I, IV, V).
VNTNM.=+#6**+'R.!*(2,'$#/$'(%6%.A61Q*(.A,'+1-.. . .
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Samples were amplifi ed by PCR, exon by exon, using primers labeled 
with fl uorescent dyes (6-carboxyfl uorescein, 6-FAM, for the forward 
primer and 4,7,2’,4’,5’,7’-hexachloro-6-carboxyfl uorescein, HEX, for 
the reverse primer). # e CE-SSCP analysis was performed as described 
earlier 163. Briefl y, after the PCR-amplifi cation, the samples were diluted 
1:20 and 1µl of the diluted sample was mixed with 10,5 µl deionized for-
mamide, 0,5 µl NaOH (0,3 M) and 0,5 µl GeneScan 350 TAMRA size 
standard (Applied Biosystems). # e samples were denatured at 95 ºC for 
5 min, and put directly onto ice. # e CE-SSCP analysis of TP53 exons 
5–9 was performed in ABI PRISM 310 capillary sequencer or in ABI 
PRISM 3100-avant capillary sequencer (Applied Biosystems) at 30 ºC. 
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In some cases with unclear results, additional running temperatures were 
used. Mutations were detected as mobility shifts and/or changes in the 
electrophoregrams (I, III, IV). 
VNTNT.>(1+,&'61Q.K'+-6(1,.K(*.!*(2,'$#/$'(%6%.. .
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After PCR-amplifi cation of DNA, the DGGE-analysis was run as de-
scribed earlier 156. Briefl y, 1-mm thick gels containing 7 % acrylamide 
(Bio-Rad) and 0,3 % bis-acrylamide (Bio-Rad) in 1x Tris-acetate-EDTA 
(TAE) buff er were used. Formamide (Merck) and urea (Merck) were 
used as denaturing agents at diff erent concentrations, 100 % denaturant 
corresponding to 9 M formamide and 7 M urea. # e gel polymeriza-
tion was activated using ammonium persulfate (Bio-Rad) and TEMED 
N,N,N’,N’-tetramethylethylenediamide (Bio-Rad). # e samples were 
run in perpendicular gels in 1x TAE buff er at 60 ˚ C in DCode Universal 
Mutation Detection System apparatus (Bio-Rad). # e electrophoresis 
time was 4 h using 150 V electrophoresis voltage. # e gels were stained 
with ethidium bromide (Aldrich-Chemie) and photographed with a UV 
transilluminator (Stratagene Eagle Eye II) (I).
VNTNV.>6'(2,.A(_&(1261Q.
DNA was fi rst amplifi ed by PCR and the PCR-products were purifi ed 
with QIAquick PCR purifi cation Kit (Qiagen Nordic) or by using 
ExoSAP-IT (USB). # e sequencing reaction was prepared with BigDye 
Terminator v3.0 Cycle Sequencing ready Reaction kit (Applied Bio-
systems, California, USA) and sequencing was performed with an ABI 
Prism 310 capillary sequencer (Applied Biosystems) or an ABI Prism 
3100-avant capillary sequencer (Applied Biosystems). Mutations were 
only accepted if the alteration was detected both in forward and reverse 
strands. Mutations that could not be identifi ed by direct sequencing, 
probably due to the quality of DNA from the PET samples, were con-
fi rmed by at least one independent CE-SSCP from a new PCR reaction 
(I, III, IV, V). 
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Bulky DNA adducts were determined in non-tumorous peripheral lung 
DNA by the 32P-postlabelling method essentially as described before 164. 
Briefl y, DNA (4 µg) was digested overnight with micrococcal nuclease 
(Sigma) and spleen phosphodiesterase (ICN and MP Biomedicals). Ad-
duct enrichment was made with nuclease P1 (Sigma) digestion of the 
normal mononucleotides. Radiolabelling occurred with 50 µCi carrier-
free [?-32P]ATP (end-labelling grade, ICN and MP Biomedicals) and 
6 U of T4 polynucleotide kinase (USB Corporation and Fermentas). 
Multidirectional thin-layer chromatography of the radiolabelled DNA 
digests was performed on 10 × 10 cm poly(ethyleneimine) cellulose 
sheets (Macherey-Nagel) as detailed earlier 164. Radioactivity patterns 
were detected by Cerenkov counting and electronic autoradiography 
(InstantImager, Packard). Background radioactivity of the blank area, 
corrected for the size of the adduct areas was subtracted from the radio-
activity of the adduct areas. DNA adduct levels were calculated by nor-
malisation for an in vitro-modifi ed benzo[a]pyrene diol-epoxide-DNA 
standard [110 adducts/108 nucleotides] as described earlier 164. Two to 
four replicate analyses were performed with each human DNA sample 
in separate assays (III).
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COX-2 expression. Sections (4 µm) cut from paraffi  n tissue blocks on 
coated slides were incubated overnight at 37 ºC, deparaffi  nized and 
then microwaved for 4 x 5 min in 0.01 Mmm Na-citrate buff er (pH 
6.0). In order to block endogenous peroxidase activity, the slides were 
immersed in 1.6 % hydrogen peroxide in methanol for 30 min and then 
in blocking solution for unspecifi c binding sites (0.5 % BSA and 1.5 % 
normal serum in PBS). Immunostaining was performed following 
a protocol described earlier 165 with monoclonal IgG against human 
COX-2 protein peptide (Cayman Chemical Co.) at a dilution of 1:100 
overnight at room temperature. After this, the slides were treated with 
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biotinylated secondary antibody (anti-mouse IgG) at a dilution of 1:250 
(Vectastain Elite ABC kit PK-6102, Vector Laboratories) in a solution 
of 0.5 % BSA in PBS for 30 min. Antibody binding sites were visual-
ized with avidin-biotin peroxidase complex solution (Vectastain Elite kit 
PK-6102, Vector Laboratories), after treatment for 30 min, and AEC 
(3-amino-9-ethylcarbazole) liquid for 15 min. Counterstaining was done 
with Mayer hematoxylin. # e COX-2 index was calculated by multiply-
ing the percentage of COX-2 positive cells by the intensity (1–5) of the 
COX-2 staining. Cases with intensity 1 or a COX-2 index less than 40 
were considered as negative (-), indexes 41–200 were scored as weak (+), 
201–300 as moderate (++) and over 300 as strong (+++) (II). 
p53 accumulation. Sections (4 µm) cut from paraffi  ned tissue blocks 
on coated slides were incubated overnight at 37 ºC, deparaffi  nized and 
then microwaved for 4 x 5 min in 0.01 mM Na-citrate buff er (pH 6.0). 
Immunohistochemistry (IHC) staining was performed using the Ventana 
Benchmark automated immunostainer (Tucson Medical Systems) fol-
lowing the protocols provided by the manufacturer. # e antibody used 
was DO-7 for wild type p53. # e p53 nuclear accumulation was scored 
as follows: if nuclear staining was seen in only 0–1 % of the cells, the 
case was considered as negative (-), in 2–33 % as weak (+), in 33–79 % 
as moderate (++) and over 80 % as strong (+++) (II).
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To further confi rm the COX-2 expression detected by IHC, we per-
formed a real-time quantitative PCR analysis. RNA was successfully 
extracted from 10 adenocarcinomas by using High Pure RNA Paraffi  n 
kit (Roche) according to manufacturer’s instructions. # e RNA extrac-
tion was successful for a subset of adenocarcinomas; for the remainder, 
the tissue samples were either too small or possibly too old to yield good 
enough quality RNA for the analysis. # e cDNA synthesis and real-time 
quantitative PCR (Taqman assay) with an AbiPrism 7700 Sequence 
Detector System (Applied Biosystems) were performed as described 
earlier 166. PCR primers and probes designed by Applied Biosystems 
and purchased from the company were used. # e results were expressed 
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as relative units (RU), which were calculated by the comparative CT 
method 166 (II).
VN`. A,+,6%,62+*.+1+*R%6%
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Several exposure variables were used to summarize the lifetime exposure 
to wood dust: ever-exposed versus never-exposed, total duration of ex-
posure, cumulative level of exposure (calculated by summing the total 
work history plus the job-specifi c products of level and duration), and 
average level of exposure (calculated as the cumulative level divided by 
total duration) (II, IV, V). 
# e average daily consumption of cigarettes was calculated by dividing 
the total lifetime number of cigarettes by the total duration of smoking. 
Cumulative tobacco consumption was expressed as pack-years (pack-years 
= total duration x average number of packs smoked per day; 1 pack = 
20 cigarettes) (II, IV, V).
Odds ratios (ORs) for TP53 mutations and the corresponding 95 % 
confi dence intervals (CI) were calculated by unconditional logistic re-
gression. All ORs were adjusted for age, sex and country. Quantitative 
variables related to wood dust exposure and smoking were categorized 
in three classes according to the distribution among all exposed subjects 
(unexposed, <50th percentile, ≥ 50th percentile). Other occupational 
exposures were coded into two categories (unexposed, exposed). Com-
parisons of proportions were performed using ?2 or Fisher exact tests 
(II, IV, V).
For analysis of COX-2 expression, a score ++ or +++ was considered 
positive. Fisher’s exact test (two-sided) was used to compare proportions 
of positive cases (II).
All analyses were performed using the STATA statistical package 
(Stata statistical software: Release 9. Statacorp LP 2005)
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# e statistical analyses were performed with GraphPad Prism 4.0 soft-
ware, using Fisher’s exact test and Mann-Whitney U-test. Two-sided P 
values are given (III).
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In the search for an effi  cient screening method, a series of 20 lung tu-
mour DNA samples were analyzed by three diff erent methods: CE-SSCP, 
DGGE and direct sequencing. DGGE and direct sequencing had been 
used in the laboratory earlier, while the CE-SSCP was set-up according 
to literature and evaluated against the other two methods.
Altogether 17 out of the 20 samples analyzed were found to be car-
rying a mutation in the TP53 gene; 15 (88 %) of them were detected 
by DGGE, 16 (94 %) by CE-SSCP and 12 (71 %) by direct sequenc-
ing. # us, DGGE detected one mutation less than CE-SSCP, but this 
mutation resided in the intron outside the area effi  ciently screened with 
the DGGE assay due to the primer design. # erefore those two methods 
were considered to be equally sensitive (94 %). Direct sequencing, with 
a sensitivity of only 71 %, was clearly less sensitive than the other two 
methods. In the laboratory, CE-SSCP was the easier method to use than 
DGGE. In addition, it was more easily automated and displayed good 
repeatability and documentation of data.
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A statistically signifi cant association was found between wood-dust ex-
posure and tumour histology. # e occurrence of adenocarcinoma was 
signifi cantly elevated (OR 8.8, CI 95 % 4.2–18.3, adjusted for age, sex 
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and study center) among wood-dust exposed cases when compared to 
squamous cell carcinoma (IV, Figure 2 and Table 2). # e pathology panel 
classifi ed 72 % (88/122) of the adenocarcinomas as the intestinal type 109. 
Most cases of the intestinal type of adenocarcinoma were encountered 
in wood-dust exposed individuals (64 %, 25/39). 
# e wood dust exposed cases of sinonasal cancer had mostly been 
exposed to both hardwood and softwood dusts, but the histologic type 
found almost exclusively among cases exposed mainly to hardwood 
dust was adenocarcinoma. # e cases mostly exposed to softwood dust 
exhibited more often squamous cell carcinoma than adenocarcinoma 
(the diff erence in the distribution of histologies by the type of wood dust 
exposure was statistically signifi cant, p < 0.001; IV: Figure 2). 
# e majority of patients with squamous cell carcinoma and adeno-
carcinoma were smokers, with similar proportions in both histologies. 
When adjusted for age, sex and study center, smoking was associated 
with a non-signifi cantly decreased risk of having an adenocarcinoma 
(IV: Table 2). None of the 15 wood-dust exposed cases that were non-
smokers presented with squamous cell carcinoma (13 adenocarcinomas 
and 2 carcinoma NOS). 
# e association between wood-dust exposure and histology remained 
signifi cant when further adjusting for smoking (OR for adenocarcinoma: 
12.6, 95 % CI 5.0–31.6). After additional adjustment for wood dust 
exposure, smoking was associated with a signifi cantly decreased OR of 
having an adenocarcinoma (OR = 0.4, 95 % CI 0.2–0.96). # ere were 
also cases exposed to formaldehyde (n = 59), many of them had also a 
history of wood dust exposure. # e majority of cases exposed to formal-
dehyde but without wood dust exposure (n = 19) carried squamous cell 
carcinomas (n = 15) (IV).
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Overall, about half of the 41 cases that underwent p53 immunohisto-
chemistry analysis expressed p53. No statistically signifi cant associations 
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between the exposures and p53 accumulation were found; however, the 
sinonasal cases with wood-dust exposure more often exhibited intense 
staining for p53 as compared with the non-exposed cased (p = 0.062). In 
the adenocarcinoma type of tumours, all the more strongly positive p53 
accumulations were found in non-smokers (p = 0.061) and wood dust 
-exposed cases (p = 0.15). Among cases with the squamous cell carcinoma 
type of tumours, smokers tended to show more p53 accumulation (from 
cases with higher p53 accumulation levels and data available for smoking 
history, 7/7 were smokers.) (II). 
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A high overall frequency of TP53 gene mutation positive cases (77 %, 
277/358) was found in a series of histologically confi rmed cases of sino-
nasal cancer. TP53 mutations were observed in all tumour cell types, but 
they were most common in adenocarcinoma (OR 2.0, 95 % CI 1.1–3.7; 
compared to squamous cell carcinoma). No diff erence in the TP53 mu-
tation frequency was found between intestinal type of adenocarcinoma 
(86 % 76/88) and adenocarcinoma of non-intestinal type (85 %, 29/34). 
About half of the mutated cases (51 %, 131/268) and both histologal 
types displayed concurrent mutations in the TP53 gene (IV).
TP53 mutations showed an overall, non-signifi cant association to 
wood dust exposure (OR 1.6, 95 % CI 0.8–3.1). # e occurrence of 
TP53 mutation was signifi cantly elevated in association with duration 
(≥24 years, OR 5.1, 95 % CI 1.5–17.1), average level (>2 mg/m3; OR 
3.6, 95 % CI 1.2–10.8), and cumulative level (≥30 mg/m3 x years; OR 
3.5, 95 % CI 1.2–10.7) of wood dust exposure. # e association between 
mutation and a long duration of wood dust exposure remained when 
analyzing the histological types separately, even though the increased odds 
ratios for TP53 mutation were statistically insignifi cant. Adjustment for 
smoking or formaldehyde aff ected the risk estimate for TP53 mutation 
associated with wood-dust exposure only marginally (IV).
Smoking was not associated with the overall risk of having a TP53 
mutation, but smokers were found to exhibit signifi cantly more fre-
quently multiple mutations than non-smokers (OR 2.7, 95 % 1.1–6.5; 
IV: Table 4), this was seen in both wood-dust exposed and non-exposed 
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groups (IV: Figure 4). Multiple mutations were also less common among 
cases exposed to wood dust (OR 0.5 95 % CI 0.3–1.1). 
Finally, 81 % (29/36) of the cases with exposure in the past to one 
or several other risk factors (chromium, nickel, leather or textile dust) 
carried a mutation. However, the occurrence of TP53 mutation was not 
signifi cantly associated with any of these exposures (IV).
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Direct sequencing was successful in identifying the type and location 
of 159 TP53 mutations of the 477 sequence alterations detected in 
the 277 mutation positive sinonasal tumours. More than half of the 
mutations (60 %, 95/159) were missense mutations; there were also 
28 (18 %) frameshift or nonsense mutations, and 36 (23 %) intronic 
or silent mutations. 86% (19/22) of the silent mutations detected were 
in tumours with multiple mutations (V: Figure 2). # e distribution of 
mutation types diff ered signifi cantly between the diff erent histologies 
(V: Figure 2), exposure groups (Figure 4) and tumours with single or 
multiple mutations (V: Figure 4). 
# e mutations were scattered over a large number of codons (IV: 
Figure 3), with codon 248 was the most frequently mutated codon with 
8 mutations (5 CGG to CAG and 3 CGG to TGG). It was followed in 
frequency by codon 135 (7 mutations; 5 TGC to TTC and 2 TGC to 
TAC), codon 175 (5 mutations; all CGC to CAC), and codon 179 (5 
mutations; 2 CAT to CTT, 1 CAT to CGT and 1 CAT to TAT). # e 
most common base change detected was a C to T transition (43/125, 34 % 
of base changes in the coding region; V: Figure 3). In particular, C to 
T transitions were frequent among the silent mutations (16/22, 73 %), 
and they were most often found in non-wood dust exposed sinonasal 
cancer cases (V: Figure 3). # e G to A transition was the second most 
common base change with 27 mutations (22 % of base changes in the 
coding region) found mainly in smokers (V: Figure 3). G to T transver-
sions occurred at a frequency of 10% (of mutations in the coding region, 
12/125) and they were detected predominantly in smokers (V: Figure 
3) and resulted in missense mutations. Frameshift mutations were also 
common, they represented the third most frequent type of mutation 
(20/159, 13 % of all mutations).
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A total of 48 sinonasal cancer tumours were analysed for COX-2 
expression by immunohistochemistry. COX-2 was expressed at high 
levels in adenocarcinoma as compared to squamous cell carcinoma (p 
< 0,001; II: Table 1). COX-2 expression showed signifi cant association 
with occupational exposure to wood dust (p = 0.024, II: Table 1), and 
with non-smoking status (p = 0.001, II: Table 1). All but one (92 %; 
12/13) of the adenocarcinoma tumours exhibiting moderate or strong 
COX-2 expression were adenocarcinomas of intestinal type. No associa-
Figure 4. Distribution of TP53 mutation types of in sinonasal cancer subdi-
vided according to different exposures as identifi ed in V. A) Mutation profi les 
of wood dust exposed and non-exposed, B) Mutation profi les of smokers 
and non-smokers.
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tion between COX-2 expression and tumour site or tumour grade was 
observed. # e association between p53 accumulation as detected by 
immunohistochemistry and COX-2 expression was close to statistical 
signifi cance in adenocarcinomas (p = 0.054) but not in squamous cell 
carcinomas (II).
When looking at the relation of COX-2 expression and TP53 muta-
tion by diff erent histological cell types or by wood dust exposure (Figure 
5), it seemed that COX-2 was mainly expressed in tumours with TP53 
mutation and adenocarcinoma histology and/or wood-dust exposure.
Figure 5. The relationship between COX-2 expression and TP53 mutations 
in sinonasal cancer subdivided according to: A) histology and B) wood-dust 
exposure. (-/+): weak or no expression of COX-2; (++/+++): moderate or 
strong expression of COX-2; TP53 M: mutated TP53 gene; TP53 WT: wild-
type TP53 gene.
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COX-2 expression could also be detected at the mRNA level. # is 
analysis was performed only on a subset of adenocarcinomas (10 cases) 
due to limitations with tissue material available. # e levels of COX-2 
mRNA expression detected by real time quantitative PCR were in most 
cases comparable with the expression determined by immunohisto-
chemistry (Pearson correlation coeffi  cient between the immunohisto-
chemistry index and the relative unit of real time quantitative PCR was 
0.63) (II). 
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In total, 45 % (47/104) of the cases, 55 % (34/62) of men and 31 % 
(13/42) of women, carried a TP53 mutation. In all, 51 TP53 muta-
tions were detected; 48 cases had a single mutation, two cases carried a 
double mutation, and one case displayed three diff erent mutations. # e 
prevalence of TP53 mutations was statistically signifi cantly associated 
with duration of smoking (55 % in those who had smoked more than 
20 years vs. 14 % in those who had smoked less, p = 0.002), tumour 
histology (70 % in SCC vs. 31 % in adenocarcinoma, p = 0.0002) and 
gender (55 % in men vs. 31 % in women, p = 0.045) 9 (III). 
Smokers (combined group of current and short-term former smok-
ers who quit less than year before surgery) had approximately twice as 
high a level of bulky adducts as the combined group of former and never 
smokers (10.9 ± 6.5 vs 5.5 ± 3.4 adducts /108 nucleotides, p<0.0001). 
Among former and never smokers, higher levels of bulky DNA adducts 
were detected in non-tumorous lung tissue from TP53 mutation carriers 
as compared to non-carriers (P = 0.076) (III) (Figure 6). In the group 
of current smokers, the carriers of wild type TP53 gene had a slightly 
higher level of bulky DNA adducts, whereas in the group of short-term 
former smokers the TP53 mutation carriers tended also to have higher 
levels of bulky DNA adducts (Figure 6). 
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Figure 6. Bulky DNA adducts in non-tumorous lung tissue from lung cancer 
patients and their relation with TP53 gene mutation and smoking status. 
Short-term former smokers gave up smoking less than one year before the 
surgery and former smokers more than a year before surgery. SD = standard 
deviation, M = mutant, WT = wild type.
# e overall codon distribution of the mutations followed the pattern 
reported in the IARC database for lung cancer. # e most commonly 
mutated TP53 codon was codon 175 (3 mutations), followed by codons 
146, 157, 248 and 266, each with two mutations. All but one of the 
mutated codons in tumours from never smokers were diff erent from those 
mutated in smokers. # e most common sequence change detected was 
a G to A transition (8/43, 19 %, in addition there was one intronic g 
to a change), followed by G to T transversion (8/43, 19 %), frameshift 
mutation (7/43, 16 %) and G to C transversion 7/43, 16 %) (III: Figure 
2). G to A transitions were more commonly seen among former smok-
ers and never smokers than among smokers (III: Figure 2). A G to T 
transversion was detected exclusively in smokers and their carriers were 
those found with a high burden of bulky DNA adducts in their lungs 
(III: Figure 2). # e majority of G to C transversions was also detected 
in smokers (III: Figure 2). Frameshift mutations were frequently seen in 
smokers (4/12, 33 %), who had smoked for more than 35 years; none 
was detected in smokers who had smoked for 20 or fewer years (III). 
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Tumour suppressor TP53 gene mutations are an important feature of 
many kinds of human cancer, as the aberration of p53 function is required 
at some point of carcinogenesis in most, if not all, human cancers 52. 
# e TP53 gene encodes a transcription factor that among its other func-
tions is known to induce DNA repair or trigger apoptosis in response to 
cellular DNA damage 64, features that are both important in inhibiting 
tumour initiation and growth. Certain carcinogenic exposures have been 
shown to induce a typical and recognizable TP53 mutation spectrum 15, 
51, 78, which makes TP53 an interesting gene for studies with a molecular 
epidemiology approach. # is work studied TP53 mutations in sinonasal 
cancer and lung cancer, two exposure-related human cancers. 
Both sinonasal and lung cancer have clear exposure-related risk 
factors. With respect to lung cancer, the primary risk factor is tobacco 
smoking 5, 141, 142, with 10- to 20-fold increased risk of lung cancer for 
smokers compared to never smokers 5, 112, 143. Smoking is associated with 
all the histological types of lung cancer 5, 88, 112, 144. Sino-nasal cancer is 
strongly associated with wood dust exposure, especially the adenocar-
cinoma histological type 7–10, as was also found in this study (I). # e 
odds ratios have been particularly high among cases with history of 
occupational exposure to hardwood dust and tumour of intestinal-type 
adenocarcinoma histology that originates from the ethmoidal sinus 7–10. 
In addition to wood dust, also smoking has been reported to increase the 
risk of sinonasal cancer, with a two- to threefold increase in risk among 
smokers and a reduction in risk among long-term quitters 112, 113, but this 
association has been suggested to be limited to squamous cell carcinoma 
and no clear association has been observed for the adenocarcinoma his-
tological type of sinonasal cancer 112, 113. 
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Earlier, TP53 mutations in sinonasal cancer have been studied in 
only a few relatively small studies 131, 133–135, whereas the TP53 muta-
tion profi le in lung cancer has been established by numerous studies 
and is well described in the TP53 mutation databases 68, 167. # e current 
studies showed that TP53 mutations were frequent in both sinonasal 
cancer (IV, 77 % overall TP53 mutation frequency) and lung cancer (III, 
45 % overall TP53 mutation frequency). In both cancers, TP53 muta-
tions were observed to be associated with exposure. In sinonasal cancer, 
the odds ratios for TP53 mutation were signifi cantly increased with 
the duration and average and cumulative level of wood dust exposure 
(IV) well in line with epidemiologic data demonstrating an association 
between duration and level of wood dust exposure and elevated risk of 
sinonasal adenocarcinoma 9, 10. Smoking did not infl uence the overall 
risk of having TP53 mutations in sinonasal cancer (IV). In lung cancer, 
it was noted that the current smokers carried more often mutations than 
former smokers and the frequency of mutations increased with increasing 
duration of smoking (III), which is in accordance with earlier studies 
and the epidemiological evidence of associating heavy and persistent 
smoking with high risk of lung cancer 112, 144, 168.
# e highest frequency (86 %) of TP53 mutations in sinonasal cancer 
in the present study was found in adenocarcinoma type of tumours (IV), 
however, there was no diff erence between the intestinal type of adenocar-
cinomas and the non-intestinal type of sinonasal cancer (IV). Squamous 
cell carcinomas exhibited also a high frequency of mutations (74 %). 
Nevertheless, the adenocarcinoma cases had a statistically signifi cant, 
two-fold increased occurrence of TP53 mutations in comparison to 
squamous cell carcinoma (IV). In lung cancer, the prevalence of TP53 
mutations was particularly high (70 %) in squamous cell carcinoma 
histological type, higher than reported for the same histological type 
in the IARC database (49 % 58). # is may refl ect the eff ect of having 
a relatively high proportion of heavy smokers included in the series of 
lung cancer patients (III). On the other hand, the mutation frequency 
detected in the adenocarcinoma type of lung cancer was very close to 
that reported in the database (III).
Interestingly, about half of the sinonasal tumours with TP53 muta-
tions carried a mutation not only in one but in two or more of the exons, 
(IV); we also found a few similar cases in lung cancer (III). In sinonasal 
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cancer, the occurrence of multiple mutations was signifi cantly associated 
with smoking; this could be seen in both wood-dust exposed and non-
exposed cases (IV). Earlier, multiple mutations have been reported also 
in squamous cell carcinoma of the head neck 169, 170, for which smoking 
and alcohol consumption are known to be the most important risk fac-
tors 171.
# e codon distribution of mutations in sinonasal cancer and lung 
cancer in the present studies followed overall the general pattern found 
in human cancer 58 and mutations were scattered over a large number 
of codons (IV, V and III). Both cancers had mutations in the hotspot 
codons 175 and 248, but also some diff erences were found. In lung 
cancer (III), one of the most mutated codons was the codon 157, which 
is frequently mutated in smoking-associated lung cancer but not found 
in non-smokers 51, 144, 155. It has been experimentally identified as a site 
of adduct formation by benzo[a]pyrene 172, 173. Accordingly, we found 
both of the codon 157 mutations in smokers. In sinonasal cancer, the 
codon 135 was one of the most commonly mutated codons (V). Gener-
ally, codon 135 mutations are not considered to be hot spots in human 
cancer, even though spontaneous codon 135 mutations have been found 
in untreated human p53 knock-in (Hupki) murine embryonic fibroblast 
cells. Interestingly, the types of mutation observed in codon 135 code 
for proteins with highly impaired transactivation capabilities 174. # e 
codon 135 mutations in Hupki cell line have been proposed to be due 
to oxygen radicals in cell culture incubators 175. As the generation of ROS 
is likely to be one of the cellular consequences of wood dust exposure 
and the subsequent infl ammatory process 116, a ROS -related induction 
of the codon 135 mutations would seem plausible. 
When examining the mutation profi le, there were diff erences be-
tween the distribution of the mutation types in lung cancer (III) and in 
sinonasal cancer (V). In lung cancer, it was noted that the most com-
mon base change was G to T (19 % of mutations), found exclusively in 
smokers. # is is in line with the TP53 mutation databases 58, 68, where 
the TP53 mutation profi le in lung cancer contains about 30 % of G to T 
transversions, seen often in hot spot codons 176, 177. G to T transversions 
have also been found in non-tumorous lung tissue from smoking lung 
cancer patients 51. # is specifi city of mutation type is compatible with 
the evidence associating DNA adducts with the types of mutations en-
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countered after exposure to benzo[a]pyrene and other PAH compounds 
176, 178, 179. # e PAH-related bulky DNA adducts have been shown to be 
present in the non-tumorous lung tissue from smokers and cause G to T 
transversion in vitro 51, 180. For the fi rst time, the present study was able 
to demonstrate that the majority of the lung cancer cases exhibiting a G 
to T transversion were indeed those with high levels of smoking-related 
bulky adducts detected in the adjacent non-tumorous lung tissue (III). 
# ese findings strongly support the proposal that the specific mutation 
spectrum of smokers originates from continued exposure to a complex 
mixture of carcinogenic and mutagenic PAHs 176, 179, 181, 182. Other factors, 
such as selective DNA repair, are likely to participate to some extent 
in the process 172, 176, 181–183, a hypothesis supported by our results that 
among former and never smokers, higher levels of bulky DNA adducts 
were detected in non-tumorous lung tissue from TP53 mutation carriers 
as compared to non-carriers, whereas smokers had approximately twice 
as high bulky adduct level as the combined group of former and never 
smokers (III). In addition, it is probable that other carcinogens present 
in tobacco smoke also contribute to the mutation profile 140, 145, 176.
Unlike the G to T transversion in lung cancer, it was not possible to 
detect any specifi c type of mutation for sinonasal cancer (V). # e most 
common base change detected was C to T transition, which was mainly 
found in silent mutations and in tumours from non-wood dust exposed 
patients. G to T transversions were also in sinonasal cancer detected 
predominantly in smokers, they represented the fourth most common 
mutation type with 10 % of the mutations in the coding region. # e low 
prevalence of G to T transversions is in good agreement with the fi nding 
showing that smoking was not signifi cantly associated with the overall 
risk of having a TP53 mutation in sinonasal cancer (IV). # e frequency 
of missense base substitutions (59 %) detected in sinonasal cancer (V) 
was somewhat lower in comparison to the overall TP53 mutation pro-
fi le in human cancer (about 80 %), and, accordingly, the prevalences of 
frameshifts (13 %) and silent mutations (14 %) were higher than those 
generally found among mutations in the TP53 gene (9 % and 4 %, re-
spectively 58). However, the frequencies found here, with the exception 
of the number of silent mutations, were not diff erent from data on 600 
mutations reported in the database for the larger anatomical entity, head 
and neck cancer 58. 
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# ere were signifi cant diff erences in mutation profi les of sinonasal 
tumour with single or multiple mutations (V). # e prevalence of silent 
mutations in tumours with a single mutation in our data (4 %) cor-
responded to that generally reported for TP53, while almost all (86 %) 
of the silent mutations had occurred in tumours exhibiting multiple 
mutations. Overall, silent and non-splice site intronic TP53 mutations 
represented 33 % of all mutations detected in sinonasal tumours carrying 
multiple mutations. # e higher frequency of silent mutations might be 
explained by their predominant occurrence concurrently with another 
mutation. Tumours with multiple mutations may refl ect a process in 
which more mutations have been able to accumulate in the tumour with 
the mutagenic pressure of tumour progression, while the TP53 mutation 
may not have been the initiation or driving force in the tumorigenesis.
In addition to silent mutations, frameshift mutations were more 
common in the sinonasal tumours with multiple mutations than in the 
single mutation tumours, but overall the frequency resembled the data 
from head and neck cancers, in which frameshift mutations have been 
reported to occur more commonly than in other cancer types 58, 171. In 
head and neck squamous cell carcinoma, frameshift mutations are often 
found in the subgroup of patients using both tobacco and alcohol 171. It 
can be speculated that similarly in sinonasal cancer, the regular, continued 
presence of two mutagenic and carcinogenic exposures, wood dust and 
tobacco smoking, may generate a continual high genotoxic stress in the 
target cells, resulting in an excess of frameshift mutations. In lung cancer 
(III), we found frameshift mutations frequently in smokers, who had 
smoked for more than 35 years (33 % of them carried a frameshift muta-
tion); none of these types of mutation was detected in smokers who had 
smoked for 20 or fewer years. Typically, frameshift mutations represent 
about 11 % of the mutations found in lung cancer of smokers 58.
Multifactorial pathways are most likely involved in the development 
of cancer. One mechanism proposed for both sinonasal cancer and 
lung cancer involves infl ammation. In sinonasal cancer, we found that 
COX-2 overexpression was associated with wood dust exposure and 
adenocarcinoma histological type (II). In the cases with adenocarcinoma 
or history of wood dust exposure, COX-2 was detected in tumours with 
TP53 mutation. Wood dust has been shown to induce an infl ammatory 
response as well as genotoxicity in experimental studies 116–119. DNA-
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damage may, at least partially, be due to production of ROS and it seems 
to be independent of the cytokine-induced infl ammation 116, 117. 
Interestingly, COX-2 expression was also associated with non-smoking 
(II) in sinonasal cancer, whereas in lung cancer, cigarette smoke has been 
shown to cause proinfl ammatory changes 184 and COX-2 overexpression 
has been detected in lung tumours 89. Also, increased levels COX-2 have 
been detected in the exhaled breath condensate of non-small cell lung 
cancer patients compared to the control group without cancer 185. Among 
cancer patients, increased levels of COX-2 were observed in smokers 
and ex-smokers compared to non-smokers and the exhaled COX-2 cor-
related with smoking as measured in pack-years 185. Furthermore, it was 
shown recently that infl ammatory mechanisms account for the tumour-
promoting eff ect of exposure to tobacco smoke on lung cancer in mice 
186. Altogether, these results support the hypothesis that infl ammation 
related to smoking participates in the development of lung cancer 4.
Technological advances and the sequencing of human genome 
have made it possible to analyze whole cancer genomes 22, 38. # is has 
revealed that relatively few gene alterations are constantly implicated in 
the development of a tumour 22. On average, there are about 80 amino-
acid altering mutations in a typical cancer but only a subset, less than 
15 mutations, are likely to contribute signifi cantly to the initiation or 
progression of the tumour 28. # ese genes include well-known oncogenes 
and tumour-suppressor genes like KRAS and TP53, but new genes have 
also been identifi ed 22, 27, 28, 74. Importantly, the data from cancer genome 
analyses have confi rmed the cancer-specifi c information obtained earlier 
by studying TP53 mutations 27, 62. As the TP53 mutations have been 
shown to associate with exposure-related DNA damage, they have been 
suggested to be useful as biomarkers in molecular epidemiology and to 
help to dissect the role of carcinogenic exposures in tumorigenesis 22, 27. 
# is type of information is important for risk assessment and preven-
tion. 
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# e present study showed that CE-SSCP is a sensitive and reproduc-
ible assay for screening of unknown TP53 mutations in human tumour 
samples. # e sensitivity of mutation detection in CE-SSCP was higher 
than in direct sequencing, and it was less laborious than DGGE. Ul-
timately, though, the DNA alterations found with CE-SSCP must be 
sequenced for the identifi cation of the exact type and location of the 
altered sequence.
Tumour suppressor TP53 gene mutations are frequently encountered 
in sinonasal cancer and they are associated with wood dust exposure at 
work. # e occurrence of TP53 mutations increased signifi cantly in as-
sociation to a long duration and a high level of occupational exposure 
to wood dust. Smoking was not observed to infl uence the overall risk 
of having a TP53 mutation in sinonasal cancer, but was associated with 
multiple TP53 mutations. # e highest frequency of TP53 mutations was 
found in adenocarcinoma type of tumours, but no diff erence was found 
between the intestinal type of adenocarcinomas and non-intestinal type 
of sinonasal cancer. # e data, together with earlier studies, suggest that 
mutational mechanisms, especially the mutations of TP53 are important 
in sinonasal carcinogenesis related to wood dust exposure. 
# e overall codon distribution of mutations in sinonasal cancer in 
the present study followed the general pattern found in human cancer 
with the mutations scattered over a large number of codons. A specifi c 
feature in the TP53 mutation distribution in sinonasal cancer was that 
the codon 135 was one of the most commonly mutated codons. Gener-
ally, this codon is more rarely mutated in human cancer. Based on some 
earlier experimental data, it is possible that mutations of this codon in 
sinonasal cancer are related to wood-dust induced infl ammation and the 
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subsequent ROS production. Sinonasal tumours from individuals with a 
history of wood dust exposure exhibited predominantly missense muta-
tions, whereas tumours from smokers contained an excess of frameshift 
and silent mutations in TP53. # e mutation profi le of TP53 in sinonasal 
cancer further points towards high genotoxic stress generated by regular 
exposure to carcinogenic substances such as wood dust. 
Infl ammation appears to play a role in sinonasal carcinogenesis as 
suggested by the results that COX-2 expression was associated with ad-
enocarcinoma type of tumours, wood dust exposure, and non-smoking. 
Among the adenocarcinomas or cases with wood dust exposure history, 
COX-2 expression appeared to occur in tumours carrying also a TP53 
mutation. In all, taking into account the mutation profi le in sinonasal 
cancer, together with the high overall frequency of TP53 mutations, sino-
nasal carcinogenesis related to wood-dust exposure appears to be a process 
where both high genotoxic stress and infl ammation, play a role. 
In lung cancer, a statistically signifi cant association between TP53 
mutations and duration of smoking, gender, and tumour histology 
was found. Furthermore, the patients with a tumour carrying a G to T 
transversion, a mutation commonly found in association with tobacco 
smoking, had a high level of smoking-related bulky DNA adducts in 
their non-tumorous lung tissue. Among former and never smokers, 
higher levels of bulky DNA adducts were detected in non-tumorous lung 
tissue from TP53 mutation carriers as compared to non-carriers. # ese 
results underline the distinctive role of the mutagenic and carcinogenic 
tobacco smoke components as the origin of specifi c mutation spectrum 
typically found in smokers. 
Sinonasal and lung cancer are cancers related to exposures to agents 
with a DNA damaging capacity. In both cancers, the mutation of TP53 
gene appears to be a key element, and it shows association with the ex-
posure. # ese exposures associated with the mutation load are typically 
regular and take place over a relatively long period of time. # e informa-
tion on molecular alterations in exposure-related human cancers adds to 
the observations from epidemiological studies and helps to understand 
the role and eff ect of diff erent etiological factors, which in turn can be 
benefi cial for risk assessment and prevention. For example, the data as-
sociating wood-dust induced infl ammation not only with asthma and 
asthma-like symptoms but also with molecular pathways of sinonasal 
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cancer could well provide further motivation to reduce wood-dust ex-
posure in the occupational setting. 
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In 2008, cancer killed almost eight million people and that 
number is predicted to increase. A large proportion of human 
cancers are preventable; many cancers have environmental risk 
factors, such as tobacco smoking and work-related exposures. 
Carcinogenesis is driven by alterations in the sequence and func-
tion of genes involved in many crucial cellular processes. Under-
standing these molecular mechanisms will clarify the role and 
biological effects of these risk factors. 
 
In this work, mutations in the tumour suppressor gene, TP53, and 
their associations with exposure were studied in sinonasal can-
cer and lung cancer. Another important mechanism in cancer is 
inflammation and its contribution was explored by analyzing the 
expression of COX-2 in sinonasal cancer.
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